InnovationsKapital: Latest News

companyNews - 16 August, 2010 - 21 Grams: 21 Grams win the coveted 2010 Customer Service World Mail Award

2010-08-18 13:36:56

21 Grams have won the coveted 2010 Customer Service World Mail Award for it's C/O (Care Of) administration service that provides end to end postage cost control – a significant offering for mailers to better manage their postage/costs, and reduce postal related administrative costs and claims. 21 Grams were on a prestigious shortlist, accompanied by Post Denmark and Australia Post – judging criteria was based upon those companies that demonstrated delivering exceptional and industry-leading customer service. “I believe that the World Mail Awards scheme is the first class incentive to encourage excellence and best practice among world’s postal organisations” - Thomas Leavey, Former Director General, Universal Postal Union (UPU) The C/O service developed by 21 Grams provides an answer to many questions relating to postal revenue protection – wide-spread application of the creative software tool, iSort™, and the C/O service could increase the level of confidence towards postal operators, especially in the liberalised European markets, where we see a significant increase in postal governance requirements for mailers. 21 Grams C/O administration service provides a service for managing companies’ current and future Postal operator agreements. This end to end postage cost control C/O service provides monitoring, control and billing through managed mail submissions to one or more Postal operators that the company has agreements with. A pre-requisite for the administration services is that the iSort™ software platform is installed and operational at your Print operator, either an in-house print & mail centre or at your selected external print & mail partner. 21 Grams thereby helps companies find and eliminate errors in postage administration, through the effective use of iSort™ technology, to provide better control of their postal and print & fulfilment operators, less postal related administrative work and much easier budgeting for future purchasing of postage. About: 21Grams was formed in 2004 and provides a number of products and services to the postal industry - they have offices in Sweden and the UK, and currently operate in the UK and throughout Scandinavia. Contact information: Tony Edwards Regional Director UK & Ireland 21 Grams Limited Regus House Malthouse Avenue CARDIFF CF23 8RU tony.edwards@21grams.com www.21grams.com

companyNews - 27 July, 2010 - Martin Dawes: Meridian Energy Selects Martin Dawes Analytics to Detect & Eliminate Data Issues that Degrade Financial Performance

2010-08-12 17:04:06

Meridian Will Leverage Lavastorm Daily to Develop, Test, and Improve Business Rules and the Conditional Logic Used for Handling Tariffs Martin Dawes Analytics (MDA), a global process analytic software and solutions provider, today announced that Meridian Energy has selected its Lavastorm Analytic Engine to ensure the accuracy of tariffs. Meridian, the largest state-owned electricity generator in New Zealand, provides both time of use (TOU) and non half hour (NHR) tariffs to its residential users, and provides a range of tariff packages for its commercial and industrial (C&I) customers. In an effort to streamline its billing accuracy process, Meridian’s Tariff Team is using Lavastorm’s software to more quickly detect and eliminate the data or logic inaccuracies that could lead to rating errors. “MDA’s software is enabling us to be significantly more accurate with less effort and time,” said Linda Perkins, Retail Operations Manager at Meridian Energy. “The combination of a substantially more complex business with the pressures to deliver financial performance made MDA an easy and powerful choice. The tool is so flexible that we already see the opportunity to apply its analytic rigor to customer analytics, meter analytics, usage analytics, and settlement.” MDA’s software is enabling Meridian to improve the accuracy and response time of its operations. The ability to gain full visibility into the data and achieve accuracy has two different values: it improves the speed of detection and resolution of rating errors and it has validated a number of rating errors that were previously thought to be inaccurate. This reduction in rating errors is improving revenue performance and the over-all customer experience, while the elimination of false positives is significantly improving the productivity of the resolution team. “The transition to Smart Grid will dramatically increase both the data and business logic complexity for Utilities, which are already highly complex operations”, said Drew Rockwell, CEO of MDA. “Meridian understood that their analytic and control capability could be improved to better manage that complexity which risks financial, operational, and customer performance. The combination of our technology and the ingenuity of their teams mean that they can put controls in place that maximize revenue today, and de-risk Meridian’s further movement to Smart Grid operations.” For more information please visit www.martindawessystems.com

companyNews - 9 July, 2010 - Santaris: European Biopharmaceutical Enterprises Appoints Søren Tulstrup, President & CEO of Santaris Pharma A/S, to its Board of Directors

2010-08-12 16:55:24

Brussels, 9 July 2010 – At its annual General Assembly held in London, the members of European Biopharmaceutical Enterprises (EBE) unanimously elected Marc de Garidel (Amgen) as the new EBE President for a 2-year term. Mr. de Garidel is Vice-President South Region of Amgen International, based in Zug, Switzerland. He had already been an active member of the EBE Board as EBE Vice-President & Treasurer since April 2006. Marc de Garidel takes over the EBE presidency from Dr. Carlo Incerti, Senior Vice President Global Market Access at Genzyme, who will continue to sit on the EBE Board as Vice-President. Thanking EBE member company delegates upon his election, Mr. de Garidel said that he was eager to further drive the development of EBE as a strong voice for biopharmaceuticals in Europe, building on solid foundations and numerous achievements during Dr. Incerti’s successful EBE presidency for the past four years. The new EBE President also expressed great confidence in the new, enlarged Board of Directors, which was elected to act on behalf of the 63 EBE member companies. Together with EBE members and the association’s staff based in Brussels, the Board will continue to deliver on the collective mission of fostering a favourable business and regulatory environment for biopharmaceutical companies of all sizes operating in Europe. Top industry executives who were elected for the first time on the EBE Board of Directors include Dr. Roberto Gradnik, Executive Vice-President at Merck Serono (Switzerland); Dr. Edwin Moses, Chairman & CEO of Ablynx (Belgium); Søren Tulstrup, President & CEO of Santaris Pharma (Denmark); Dr. Ralf Schumacher, Head of Biologics Research at Roche (Switzerland); and Dr. Ignacio Faus, CEO of Palau Pharma (Spain). For the full EBE Board list, please visit the EBE website here. For more information, please contact: Emmanuel Chantelot, Executive Director, EBE +32 2 626 2561 emmanuel@ebe-biopharma.org About EBE European Biopharmaceutical Enterprises (EBE) is the Brussels-based European trade association that represents biopharmaceutical companies of all sizes operating in Europe. It has 63 member companies engaged in the research, development and manufacturing of innovative medicinal products using biotechnology. EBE also operates as the biotechnology arm of EFPIA, the European pharmaceutical industry federation. Visit: www.ebe.biopharma.org www.santarispharma.com

companyNews - 5 July, 2010 - Apptus: Online book retailer Bokus prepares for the future with Apptus eSales

2010-08-12 12:55:00

Lund, Sweden, July 5, 2010 – Apptus Technologies AB, a leading provider of eCommerce search and recommendations solutions, today announced that Bokus (www.bokus.com) has launched their new-look eCommerce website incorporating Apptus eSales, its new personalised search and recommendations suite. Bokus is one of Sweden’s largest online book retailers, carrying nearly 6 million titles. In 2009, their eCommerce site received up to 80,000 visitors per day and delivered 8,000 – 15,000 books per day, using an early product from Apptus for their site search and navigation. After merging with Akademibokhandeln in 2008, Bokus embarked upon a significant redesign of their existing website, including a competitive re-evaluation of both organisations’ eCommerce suppliers. Mats Fagerström, Bokus’ eCommerce Director, chose to focus on improving their customers’ whole online shopping experience. The company was impressed by Apptus’ vision of aligning and optimising all aspects of the site’s interaction with shoppers, observing customer behaviour to personalise site search, navigation and recommendations in an integrated way. “Not only were we looking for impressive product features, but also for a company whose product vision aligns with our ambitions for an increasingly personalised website”, Mats Fagerström said. Apptus has provided Bokus with a robust search capability designed to help shoppers overcome the challenge of spelling authors names or remembering exact titles. Did-you-mean and auto-complete suggestions come in categories, complementing eSales’ flagship high performance ‘incremental search’, which returns results as the user types. Buyers can zoom in on what they want by filtering and sorting in many ways, and for those who aren’t quite sure what they are looking for, eSales’ socially-driven recommendations will give them plenty of ideas. “Bokus has always aimed to offer more than books,” says Cecilia Nilsson, Bokus Site manager, “we want to develop a long term relationship with our customers, one in which we can tailor a better service for each individual’s needs. We have a lot of plans for the website over the next few years, and Apptus eSales will help us deliver them.” The companies are already talking about leveraging the new technology in support of Bokus’ outbound marketing efforts. “Bokus is a great example of a company thinking about their technology as an investment in long term revenue growth,” says Michael Mokhberi, CEO at Apptus. “By offering focused search, navigation and recommendations relevant to shoppers interests, Bokus will improve the whole online experience for their customers, leading to increased sales and more return visits.” For more information, please contact: Michael Mokhberi, CEO at Apptus +46 701664102 michael.mokhberi@apptus.com Bokus is an online bookshop with over 6million titles. Bokus is part of Akademibokhandeln, Sweden’s largest bookstore chain with 62 stores across the country and approximately 700 employees. Akademibokhandeln is 100 percent owned by KF. Apptus is Sweden’s leading e-commerce search & recommendations solution provider, offering an integrated site search & navigation, recommendations and reviews solution that learns from user behaviour and acts to make each individual shopper’s experience increasingly personal and relevant. Founded in 2000, Apptus has delivered large-scale, multi-site, multi-language solutions to some of the world’s largest retailers and online directory suppliers across 18 countries, including CDON, Bokus, ATEA, Fonecta, Hitta and Yell.com. Apptus is headquartered in Sweden with sales offices in the UK, Switzerland and Canada. For more information please visit www.apptus.com

companyNews - 23 June, 2010 - Santaris: Santaris Pharma A/S and miRagen Therapeutics, Inc. Form Strategic Alliance to Develop microRNA-targeted Medicines for the Treatment of Cardiovascular Disease

2010-08-12 12:50:40

miRagen licenses rights to utilize Santaris Pharma A/S proprietary Locked Nucleic Acid (LNA) Drug Platform to identify and select drug candidates against miRagen’s proprietary microRNA targets for the treatment of cardiovascular disease
Santaris Pharma A/S obtains a minority equity interest in miRagen in addition to milestone payments and royalties on LNA-based medicines developed as part of the collaboration
miRagen, a leader in developing microRNA-based therapeutics for cardiovascular and muscle disease, is developing single-stranded LNA-based drug candidates for the treatment of patients with cardiovascular and muscle disease
Agreement demonstrates that the LNA Drug Platform is the technology-of-choice for developing RNA-targeting medicines and brings together two industry leaders in the pursuit of breakthrough therapies for unmet medical needs

Hoersholm, Denmark/San Diego, California & Boulder, Colorado, June 23, 2010 — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies and miRagen Therapeutics, Inc., a biopharmaceutical company focused on developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today that they have formed a strategic alliance to develop microRNA-targeted medicines for the treatment of cardiovascular disease. Cardiovascular disease is the number one cause of death worldwide, claiming 17.1 million lives a year, or 29 percent of all deaths globally[1]. An estimated 81 million American adults – more than one in three – have one or more types of cardiovascular disease, which include high blood pressure, coronary heart disease, congenital cardiovascular defects, heart attack, chest pain, heart failure and stroke[2]. miRagen is planning to develop and commercialize single-stranded LNA-based product candidates intended for the treatment of cardiovascular disease by utilizing Santaris Pharma A/S proprietary Locked Nucleic Acid (LNA) Drug Platform. Under the terms of the agreement, Santaris Pharma A/S received a minority equity interest in miRagen, and is eligible to receive milestone payments and royalties upon achievement of certain development and regulatory milestones. Financial terms of the collaboration were not disclosed. “We are pleased that miRagen selected Santaris Pharma A/S as its preferred partner, further validating that our LNA Drug Platform is the technology-of-choice for developing RNA-targeted medicines,” said Søren Tulstrup, President and CEO of Santaris Pharma A/S. “This collaboration is a prime example of two companies leveraging their unique capabilities in developing RNA-targeted medicines and combined expertise in cardiovascular disease to develop new medicines for life-threatening diseases. Santaris Pharma A/S looks forward to adding more alliances with biotechnology companies to its growing list of partners.” The unique combination of pharmaceutical properties, small size and very high affinity of LNA-based drugs developed utilizing Santaris Pharma A/S LNA Drug Platform allows this new class of drugs to potently and specifically inhibit RNA-targets in many different tissues without the need for complex delivery vehicles. “We are very enthusiastic about our collaboration with Santaris Pharma, which provides us with what we believe is best-in-class technology to advance our mission of developing innovative microRNA-based therapies intended for the treatment of patients with cardiovascular and muscle disease,” said William S. Marshall, Ph.D., President and CEO of miRagen Therapeutics. “Santaris Pharma’s LNA drug platform, which has produced compounds already in the clinic, can help to accelerate our development programs by providing the most effective anti-microRNA chemistry we’ve explored to date.” About microRNAs MicroRNAs have emerged as an important class of small RNAs encoded in the genome. They act to control the expression of sets of genes and entire pathways and are thus thought of as master regulators of gene expression. Recent studies have demonstrated that microRNAs are associated with many disease processes. Because they are single molecular entities that dictate the expression of fundamental regulatory pathways, microRNAs represent potential drug targets for controlling many biologic and disease processes. About Locked Nucleic Acid (LNA) Drug Platform The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combines the Company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates against RNA targets, both mRNA and microRNA, for a range of diseases including metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders. The LNA Drug Platform overcomes the limitations of earlier antisense and siRNA technologies to deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The unique combination of small size and very high affinity, which is only achievable with LNA-based drugs, allows this new class of drugs to potently and specifically inhibit RNA targets in many different tissues without the need for complex delivery vehicles. LNA-based drugs are a promising new type of therapy that enables scientists to develop drugs to attack previously inaccessible clinical pathways. The most important features of LNA-based drugs include excellent specificity, providing optimal targeting; increased affinity to targets providing improved potency; and strong pharmacology upon systemic delivery without complicated delivery vehicles. About Santaris Pharma A/S Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the Company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The Company’s research and development activities focus on infectious diseases and metabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The Company has strategic partnerships with Enzon Pharmaceuticals, GlaxoSmithKline, Pfizer, Shire plc and miRagen Therapeutics, Inc. As part of its broad patent estate, the Company holds exclusive worldwide rights to all therapeutic uses of LNA. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States. Please visit www.santaris.com for more information. About miRagen Therapeutics miRagen Therapeutics, Inc., was founded in 2007 to develop innovative microRNA-based therapeutics for cardiovascular and muscle disease. MicroRNAs are short, single-stranded RNA molecules encoded in the genome that regulate gene expression and are thought to play a vital role in influencing cardiovascular and muscle disease. Cardiovascular disease is the leading cause of death globally and represents an enormous burden on global healthcare systems. Principally funded through venture capital investments, miRagen combines world–class leadership in cardiovascular medicine with unprecedented in-house expertise in microRNA biology and chemistry. For more information, please visit www.miragentherapeutics.com This news release contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those projected and miRagen cautions readers not to place undue reliance on the forward-looking statements contained in the release. Media Contacts: Santaris Pharma A/S Navjot Rai Director, Global Communications Office: + 1 858 764 7064 ext. 206 Cell: +1 619 723 5450 navjot.rai@santaris.com miRagen Therapeutics Anna Sussman Scout Investor Relations 303-907-5358 anna@scoutir.com Breanna Burkart Scout Investor Relations 303-907-5162 Breanna@scoutir.com [1] World Health Organization - http://www.who.int/cardiovascular_diseases/en [2] Heart Disease and Stroke Statistics — 2010 Update, American Heart Association

companyNews - 21 June, 2010 - Apptus: Europe’s leading search technology company Apptus, offers a safe passage for all users of FAST on Linux and Unix to Apptus’ search platform Theca.

2010-08-12 12:38:18

Apptus, Europe’s leading developer of search and content enrichment services for online directories, today announced that they will offer all users of the FAST Enterprise Search Platform to replace it with their own platform Theca at no cost for licenses. The announcement was made as a response to the spring news that FAST’s present owner Microsoft will abandon all further Unix and Linux platform support for FAST. “It seems that Microsoft wants to focus on enterprise search and integrate FAST with their own platform. A move that will make it difficult for online directories and digital marketers who needs the benefits of a combination between deeper content and better search.” says Michael Mokhberi, CEO at Apptus. Apptus will now offer companies using FAST a safe passage to their own platform Theca, which today is used by many of the major online directories in Europe. At no cost, Apptus will analyse the companies present search situation and the online directory’s specific needs. “We offer all online directory companies a safe passage to our leading and stable platform without any additional license costs. We have been in the market for over 10 years and have obtained a leading position in Europe with our cutting edge technology in search and content enrichment. This means that we have a long term commitment and will continue to develop our products based on our customers needs, rather than our own.” says Michael Mokhberi. For more information, please contact: Michael Mokhberi, CEO at Apptus +46 701664102 michael.mokhberi@apptus.com Apptus idea is to bring buyers and sellers closer to each other by providing instant access to relevant information. Since year 2000 the company has developed solutions based on the platform Theca, which optimizes the synergies between search, content and sales. Apptus is a privately held company, headquartered in Sweden with sales organizations in Europe and North America. Among the customers are leading companies within e-commerce and online directories in 18 countries, for example Yell.com, ATEA, CDON, De Gule Sider, Eniro, Fonecta, Hitta, Lokaldelen, Panduro Hobby, Quebecor, Truvo and Bokus . For more information, please visit www.apptus.com

companyNews - 11 June, 2010 - Jolife: LUCAS™2 Chest Compression System received Silver Award in New York

2010-08-12 12:18:36

At a ceremony at New York City’s Jacob K Javitz Convention Center, in conjunction with the Medical Design and Manufacturing East Conference and Exposition this week, Jolife AB, together with its exclusive distributor Physio-Control Inc., a wholly-owned subsidiary of Medtronic, Inc. received a Silver Medical Design Excellence Award (MDEA) for its LUCAS 2 Chest Compression System. LUCAS 2 is an external medical device that provides hands-free chest compressions during CPR. The device offers many benefits to both patients and care providers, and is developed and manufactured by Jolife AB in Lund, Sweden and distributed globally by Physio-Control, Redmond, US. The MDEA competition is organized and presented by Canon Communications LLC (Los Angeles) and is the only awards program that exclusively recognizes contributions and advances in the design of medical products in the US. Judges evaluated nominees based on product innovation, design and engineering achievement, enhanced benefits to the patient, and cost-effectiveness in manufacturing and healthcare delivery. “We are honored by this recognition of the LUCAS 2 Chest Compression System,” said Erik von Schenck, CEO of Jolife AB. “In any emergency situation, time is of the essence, and products that are intuitive to use and that can be used under even the most trying circumstances are of the utmost importance. We are proud to offer LUCAS 2 through our partner Physio-Control.” About LUCAS CPR LUCAS Chest Compression System is an easy-to-use and lightweight device that provides quality chest compressions according to the European Resuscitation Council and American Heart Association Guidelines for CPR (cardiopulmonary resuscitation). It assists rescuers in maintaining vital blood circulation in cardiac arrest patients. LUCAS is simple to use, applied within seconds and feasible for use in a majority of cardiac arrest patients. LUCAS is available in an electrically driven version (LUCAS 2) and a pneumatically driven (LUCAS 1). An estimated 25 000 patients have been treated with LUCAS so far. The mechanical CPR device has shown to increase operational efficacy and to improve the opportunities to save cardiac arrest patients. About Jolife AB Jolife AB, founded in 2000, develops and manufactures the LUCAS Chest Compression System. Jolife works closely with leading physicians, nurses, paramedics and first responders and is committed to research and development in order to continue to offer innovative products. The LUCAS Chest Compression Systems are sold in 34 countries around the world. Based in Lund in southern Sweden, Jolife markets its products through an exclusive global distribution agreement with Physio-Control, Inc., a division of Medtronic Inc. – except in Sweden, Norway and Finland, where Jolife sells directly. Further information: Erik von Schenck, CEO, JOLIFE +46 46 286 5002 evs@jolife.com Or Sara Lindroth, Marketing Director, JOLIFE +46 46 286 5024 sara.lindroth@jolife.com Jolife AB Scheelevägen 17 223 70 Lund Sweden +46 46 286 5000 www.jolie.com www.lucas-cpr.com

companyNews - 8 June, 2010 - Martin Dawes: Martin Dawes Systems and Aircell Win Innovation Award for Consumer Service Innovation

2010-08-12 12:09:06

Martin Dawes Systems, an international vendor of customer management solutions for the communications industry, has won the Global Telecoms Business Innovation Award for Customer Service in recognition of their ground breaking work with Aircell, the world's leading provider of airborne connectivity. Established in 1997, the Global Telecoms Business Innovation Awards are designed to honour innovative projects involving telecoms operators and service providers around the world, in association with their vendors and suppliers. Other winners at the award conference, which was held at The Park Lane Hotel, London on June 7th, included Telefónica O2, Telstra and Verizon. Martin Dawes Systems was recognized for their role in the delivery of Aircell’s Gogo® Inflight Internet Service. Gogo allows travellers to stay connected to their world below. Today, Gogo is on more than 930 commercial aircraft and over 3,000 flights each and every day. Gogo is currently available on all AirTran Airways and Virgin America flights and on select Air Canada, Alaska Airlines, American Airlines, Delta Air Lines, United Airlines and US Airways flights Martin Dawes Systems is responsible for Gogo’s order processing and tariffs, real-time transactions, billing processes and CRM functions. In addition to delivering a new and technically innovative inflight internet service, Aircell’s business model is commercially complex with unique dynamics; airlines, passengers and enterprises all being key constituents. Martin Dawes Systems addressed this challenge by delivering a single platform to manage both Gogo subscription and transactional revenue to ensure the best possible in-cabin experience to all users of the service. The unique nature of the project also required the tailoring of services to meet end-user demands, such as dynamic pricing selection and an integrated web chat facility that enables passengers’ choice on the type of offering and real time support from Customer Support Agents. “We continue to help our customers as they become more innovative with customer care and operational excellence. This award provides independent validation of our leadership in this space,” said Dewi Thomas, Managing Director of Martin Dawes Systems. “Combined with our success in helping Aircell meet its stringent customer service standards, this independent endorsement of the project demonstrates how our focus on the customer experience resonates with the industry.” “As Aircell continues to roll out our inflight connectivity it is essential to ensure seamless customer care. The delivery of such a unique service has required us to innovate at all levels,” said Paula Niemczyk, Director IT Design and Development of Aircell. “By working with Martin Dawes Systems we have been able to not only meet our expectations from an operational perspective, but deliver a fantastic experience to the passengers who use Gogo.” For more information please visit www.martindawessystems.com

companyNews - 7 June, 2010 - Action Pharma: ACTION PHARMA OBTAINS ENCOURAGING PRELIMINARY RESULTS IN A PHASE II CLINICAL TRIAL WITH AP214

2010-08-12 12:03:04

Holte, Denmark, June 07, 2010 Action Pharma A/S obtained encouraging preliminary blinded results in the second phase II clinical trial (named CS005) with its lead development candidate, AP214. AP214 is being developed for protection of acute kidney injury in patients undergoing cardiac surgery under cardiopulmonary bypass as the lead indication. The phase II clinical trial is a randomized, double-blinded, placebo-controlled, sequential, dose-finding trial with three dose levels in 42 patients. Primary objectives are safety and tolerability. Secondary objectives include effects on kidney function/injury and on the systemic inflammatory response by determinations of changes in serum creatinine and plasma IL-6. The preliminary results are blinded without the results from statistical analyses. The results demonstrate that AP214 is well tolerated and safe at all three dose levels. At the highest dose level, AP214 prevents the increase in serum creatinine by 50-60%, and in the IL-6 response by 30-40%, compared to placebo (trends based on blinded data). This is consistent with a robust effect to prevent postsurgical acute kidney injury (AKI) and systemic inflammatory response. “The encouraging preliminary results of treatment with AP214 in the CS005 phase II clinical trial is a major milestone for Action Pharma”, says Ingelise Saunders, CEO of Action Pharma. She continues, “this also represents an important step forward in our partnering and corporate development strategy prior to the forthcoming final, unblinded data expected in September.” “Many patients in the USA and Europe each year undergo major thoracic surgery, and approximately 10-20% of these patients experience various degrees of kidney injury which again is associated with increased mortality, co-morbidity and prolonged hospitalization. Currently, there is no treatment available”, says Søren Nielsen, COO of Action Pharma. He continues, “consequently, this indication addresses a major unmet medical need, and we estimate the commercial potential to be approximately EUR 500 million with expansion potential in additional indications”. The clinical trial has been conducted in Denmark at the Department of Cardiac and Thoracic Surgery at Rigshospitalet (the Danish State Hospital) in Copenhagen, and at Odense University Hospital in Odense. For further information, please contact: Ingelise Saunders, CEO Action Pharma A/S Dronninggaards Allé 136 DK-2840 Holte Denmark ils@actionpharma.com Phone: +45 2020 3687 Søren Nielsen, COO Action Pharma A/S Dronninggaards Allé 136 DK-2840 Holte Denmark sn@actionpharma.com Phone: +45 2324 4533 About Action Pharma A/S Action Pharma is a privately owned Danish biotech company. Action Pharma develops novel drug candidates targeting melanocortin receptors and bring these to the stage of clinical proof of concept for subsequent partnering. The drug candidates are first in new drug classes and exploit novel mode of action profiles with an efficacy that is superior compared to compounds currently on the market. Action Pharma has a pipeline of several patent protected, in-house developed, drug candidates. Two drug candidates are currently in clinical development, AP1030 (completed phase IB) and AP214 (in phase II), and two drug candidates in late preclinical development. The Action Pharma team has significant scientific expertise and has published more than 400 scientific papers. AP214 is developed to prevent post-surgical kidney injury after major thoracic surgery. AP214 is currently being tested in a phase II clinical trial investigating the effect of AP214 on organ protection in patients undergoing cardiac surgery, who are at increased risk of kidney injury. Every year, more than 150,000 patients in the USA and in the EU undergo major thoracic surgery. Approximately 10-20% of these patients experience various degrees of kidney injury which again is associated with marked increase in mortality, co-morbidity and prolonged hospitalization. Currently, there is no treatment to prevent or treat kidney injury associated with major surgery. Thus there is a major unmet medical need. AP214 mediates its potent effect via the type 1 and type 3 melanocortin receptors. Results from a phase II US clinical trial, from a phase IB trial in human volunteers subjected to LPS-induced inflammation, and initial results from an ongoing phase II trial show encouraging efficacy, safety and tolerability data for AP214. Action Pharma’s proprietary small molecule program further includes compounds for treatment of metabolic diseases and/or inflammatory diseases. AP1030 and second generation compounds have potent pre-clinically documented anti-diabetic and anti-obesity effects and AP1030 administered once daily orally for two weeks in obese human volunteers results in positive effects on glucose metabolism. Thus the program has the potential for development of drug candidates that are superior to other anti-diabetics, including GLP-1 analogues, DPP-4 inhibitors and glitazones. Action Pharma develops AP1189 for oral treatment of systemic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel diseases, atopic dermatitis, COPD and others and AP1189 is ready for clinical development. Similarly, AP405 is developed for topical treatment of inflammatory skin diseases, such as atopic dermatitis and is ready for clinical development. Action Pharma has a strong investor base of leading European investors, including Sunstone Capital, Global Life Science Ventures, SLS Invest, InnovationsKapital, Inventure Capital, and Oestjysk Innovation. For more information, please visit www.actionpharma.com

companyNews - 2 June, 2010 - Jasper: Jasper Crosses the Design-to-Verification Chasm

2010-08-12 11:45:29

MOUNTAIN VIEW, Calif. – June 2, 2010 – Jasper Design Automation, provider of advanced formal technology solutions, today announced new versions of ActiveDesign™ and JasperGold® with capabilities that bridge the divide between chip design and verification by sharing a common, persistent knowledge base. Jasper’s ActiveDesign with Behavioral Indexing™ lets users design, concurrently modify, and verify their RTL code, then store it in a persistent database containing both the RTL itself and an “index” of its elastic behaviors. This information is shared downstream with the JasperGold verification team, facilitating increased collaboration between groups. Benefits are unity among multiple design groups and verification teams, a reduction in information demand on designers, acceleration of verification, and increased IP reuse since design behaviors are now archived and easily accessible. “ActiveDesign with Behavioral Indexing is the core technology that allows RTL developers to store information, building persistent value databases that can later be used by other designers or verification engineers,” said Dr. Rajeev Ranjan, Jasper Chief Technology Officer. “ActiveDesign and JasperGold work synergistically. Designers using ActiveDesign explore blocks, waveforms and their key behaviors, creating and archiving important information. ActiveDesign can then export properties (asserts, assumes, covers, in SVA and PSL) for transfer to other designers or verification teams using JasperGold.” In addition to the new unified design-to-verification flow, Jasper has added several new capabilities to its tools to increase rapid adoption, high-level verification acceleration, and increased ROI for formal verification users. ActiveDesign Version 2.0 Version 2.0 of ActiveDesign, named an EDN Hot 100 Product in January, includes the ability to share information with JasperGold as described above, along with several new, automated fast-start and collaboration features. EasyStart automates the identification of clocks and resets so designers can explore new RTL blocks faster. AutoExplore examines behaviors of interest by displaying contributing causes and paths back through the design to show causality. With concurrent modification, different designers can work on the same code while an intelligent management system prevents overwriting. ActiveDesign’s hierarchical design support lets an RTL block be instantiated repeatedly at different levels in the design to efficiently deal with complexity, and a new parallelization feature distributes ActiveDesign across multiple platforms for increased throughput. JasperGold/JasperCore™ Version 7.0 The JasperGold Formal Verification System now has 50% higher performance and capacity, aided by new engine technology and modeling abstractions. ProofGrid and new ProofGrid Manager support user-controlled and distributed proof engines to reduce the time needed to reach full proofs. A new management capability accelerates convergence of deep formal proofs, leveraging Jasper’s leading design-space tunneling and promoting both proactive and after-the-fact RTL tree exploration of design complexity. And versatile JasperGold now has enhanced handling of the toughest formal verification tasks such as X-propagation, multi-cycle path analysis, clock domain crossing (CDC), and certification of the latest protocols such as DFI and AMBA 4 (enabled by designer-friendly Jasper Proof Kits). About Jasper Design Automation Jasper delivers industry-leading EDA software solutions for semiconductor design, verification, and reuse, based on the state-of-the-art formal technology. Customers include worldwide leaders in wireless, consumer, computing, and networking electronics, with over 150 successful chip deployments. Jasper, headquartered in Mountain View, California, is privately held, with offices and distributors in North America, South America, Europe, and Asia. Visit www.jasper-da.com to reduce risks; increase design, verification and reuse productivity; and accelerate time to market. Jasper Design Automation and the Jasper Design Automation logo are trademarks or registered trademarks of Jasper Design Automation, Inc. All other trademarks mentioned are the property of their respective companies.

companyNews - 10 June, 2010 - Aepona: Aepona wins Global Telecoms Business Innovation Award for Canadian GSMA OneAPI Pilot

2010-06-11 16:52:44

The Canadian OneAPI Pilot, an initiative that makes it easy for application developers to access the network and billing assets of multiple operators, was launched by the GSMA, TELUS, Rogers Wireless and Bell Canada in February 2010, with Aepona providing the technology platform and managed services. “In late 2009 we set out, with Rogers Wireless and Bell Canada, to abstract our individual networks and billing systems and make them collectively available to developers, allowing them to easily create and monetize innovative mobile and web-based services” said Mr Gedeon. “With support from the GSMA and our technology partners Aepona, Neustar and PayPal, we delivered a commercial platform within a few months of launching the project. This platform now provides developers with commercial access to the aggregated base of 22 million subscribers in Canada.” In presenting the Awards, Alan Burkitt-Gray, editor of Global Telecoms Business, commented: “This is the fourth time we’ve run our Innovation Awards and each year we’ve seen that the industry is working harder and harder to deliver exciting and innovative services to its customers worldwide. Congratulations to all the award winners. The industry is seeing a wave of innovation which is making a huge difference — to the companies working in the industry and to all of us in business and as consumers. They are making such a difference to the world. We want to celebrate what they are doing.” About Aepona Aepona provides products and services to Telcos globally, enabling them to adopt the emerging Network as a Service (NaaS) business model and unleash the full power of their network assets. With NaaS, Telcos can profit from the current trend towards Mobile Cloud Computing by publishing and monetizing their assets as Web-based APIs towards Enterprises, Web-Based Service Providers and Application Developers. Aepona's products are used by operators globally to power 1.2 billion monthly transactions and deliver $1 billion annual revenues to operators, application and content providers. Aepona is also the technology provider for the GSMA's OneAPI initiative. For more information, visit www.aepona.com For further information contact: Michael Crossey Vice President Marketing, Aepona michael.crossey@aepona.com +44 7734 318210 www.aepona.com

companyNews - 7 June, 2010 - Cellartis: Cellartis is a partner in a ten million Euro R&D project funded through a unique initiative by the European Commission and the European cosmetic industry

2010-06-11 12:16:29

June 7, 2010, Gothenburg, Sweden Cellartis AB, a premier provider of stem cell derived products and technologies today announced that the company will be a key partner in a five years joint research and development project which is now entering negotiations to receive funding within the Health Programme of the European Commission's 7th RTD Framework Programme. The project, “ScreenTox”, will address the unmet need for test methods for predicting toxicity of drugs, chemicals, and cosmetic ingredients. Cellartis is one of 14 industrial and academic partners in the project which is coordinated by Inserm, the French National Institute for Health and Medical Research. Following successful negotiations, the ScreenTox-project will be funded as part of a research cluster comprising seven consortia with an overall budget of 50 million Euro, through a unique initiative of the European Commission and the European Cosmetics Association (COLIPA). In the development of products for use by humans it is vital to identify compounds with toxic properties at an early stage of their development, in order to avoid spending time and resources on unsuitable and potentially unsafe candidates. Human pluripotent stem cells offer an unparalleled opportunity to create a wide variety of human cell-based test systems since these cells may be expanded indefinitely and triggered to differentiate into any cell type. The ScreenTox-project aims at making use of these two attributes in order to optimise current processes and develop novel methods to achieve functional differentiation of human-based target cells in vitro. Cellartis role will be to produce and further develop human embryonic and induced pluripotent stem cell derived cardiomyocytes and hepatocytes. Marc Peschanski, coordinator of the network, underscores the major paradigm shift in predictive toxicology that pluripotent stem cells will permit in the coming years: “Evaluation of toxicants calls for new models that will allow assessing toxicity pathway responses in vitro. Derivatives of pluripotent stem cell lines are likely the best candidates to implement this new strategy, as such relevant and reliable model systems can be robust and scalable in order to meet the challenges of industrialscale screens.” “The opportunity to collaborate with some of the most outstanding researchers and companies across Europe in an area which is exactly in our core business is unique, and we are thrilled and honoured to take a very active part in the ScreenTox-project,” says Johan Hyllner, Chief Scientific Officer of Cellartis. “For everyone involved, it is also rewarding to jointly work towards the goal of providing alternatives to the use of experimental animals for testing of new drugs and chemicals” continues Johan Hyllner. Cellartis Enquiries: Dr. Johan Hyllner Chief Scientific Officer +46 31 7580902 johan.hyllner@cellartis.com www.cellartis.se

companyNews - 7 June, 2010 - Action Pharma: ACTION PHARMA OBTAINS ENCOURAGING PRELIMINARY RESULTS IN A PHASE II CLINICAL TRIAL WITH AP214

2010-06-11 12:04:44

AP214 is being developed for protection of acute kidney injury in patients undergoing cardiac surgery under cardiopulmonary bypass as the lead indication. The phase II clinical trial is a randomized, double-blinded, placebo-controlled, sequential, dose-finding trial with three dose levels in 42 patients. Primary objectives are safety and tolerability. Secondary objectives include effects on kidney function/injury and on the systemic inflammatory response by determinations of changes in serum creatinine and plasma IL-6. The preliminary results are blinded without the results from statistical analyses. The results demonstrate that AP214 is well tolerated and safe at all three dose levels. At the highest dose level, AP214 prevents the increase in serum creatinine by 50-60%, and in the IL-6 response by 30-40%, compared to placebo (trends based on blinded data). This is consistent with a robust effect to prevent postsurgical acute kidney injury (AKI) and systemic inflammatory response. “The encouraging preliminary results of treatment with AP214 in the CS005 phase II clinical trial is a major milestone for Action Pharma”, says Ingelise Saunders, CEO of Action Pharma. She continues, “this also represents an important step forward in our partnering and corporate development strategy prior to the forthcoming final, unblinded data expected in September.” “Many patients in the USA and Europe each year undergo major thoracic surgery, and approximately 10-20% of these patients experience various degrees of kidney injury which again is associated with increased mortality, co-morbidity and prolonged hospitalization. Currently, there is no treatment available”, says Søren Nielsen, COO of Action Pharma. He continues, “consequently, this indication addresses a major unmet medical need, and we estimate the commercial potential to be approximately EUR 500 million with expansion potential in additional indications”. The clinical trial has been conducted in Denmark at the Department of Cardiac and Thoracic Surgery at Rigshospitalet (the Danish State Hospital) in Copenhagen, and at Odense University Hospital in Odense. For further information, please contact: Ingelise Saunders CEO, Action Pharma A/S Dronninggaards Allé 136 DK-2840 Holte, Denmark ils@actionpharma.com +45 2020 3687 Søren Nielsen COO, Action Pharma A/S Dronninggaards Allé 136 DK-2840 Holte, Denmark sn@actionpharma.com +45 2324 4533 About Action Pharma A/S Action Pharma is a privately owned Danish biotech company. Action Pharma develops novel drug candidates targeting melanocortin receptors and bring these to the stage of clinical proof of concept for subsequent partnering. The drug candidates are first in new drug classes and exploit novel mode of action profiles with an efficacy that is superior compared to compounds currently on the market. Action Pharma has a pipeline of several patent protected, in-house developed, drug candidates. Two drug candidates are currently in clinical development, AP1030 (completed phase IB) and AP214 (in phase II), and two drug candidates in late preclinical development. The Action Pharma team has significant scientific expertise and has published more than 400 scientific papers. AP214 is developed to prevent post-surgical kidney injury after major thoracic surgery. AP214 is currently being tested in a phase II clinical trial investigating the effect of AP214 on organ protection in patients undergoing cardiac surgery, who are at increased risk of kidney injury. Every year, more than 150,000 patients in the USA and in the EU undergo major thoracic surgery. Approximately 10-20% of these patients experience various degrees of kidney injury which again is associated with marked increase in mortality, co-morbidity and prolonged hospitalization. Currently, there is no treatment to prevent or treat kidney injury associated with major surgery. Thus there is a major unmet medical need. AP214 mediates its potent effect via the type 1 and type 3 melanocortin receptors. Results from a phase II US clinical trial, from a phase IB trial in human volunteers subjected to LPS-induced inflammation, and initial results from an ongoing phase II trial show encouraging efficacy, safety and tolerability data for AP214. Action Pharma’s proprietary small molecule program further includes compounds for treatment of metabolic diseases and/or inflammatory diseases. AP1030 and second generation compounds have potent pre-clinically documented anti-diabetic and anti-obesity effects and AP1030 administered once daily orally for two weeks in obese human volunteers results in positive effects on glucose metabolism. Thus the program has the potential for development of drug candidates that are superior to other anti-diabetics, including GLP-1 analogues, DPP-4 inhibitors and glitazones. Action Pharma develops AP1189 for oral treatment of systemic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel diseases, atopic dermatitis, COPD and others and AP1189 is ready for clinical development. Similarly, AP405 is developed for topical treatment of inflammatory skin diseases, such as atopic dermatitis and is ready for clinical development. Action Pharma has a strong investor base of leading European investors, including Sunstone Capital, Global Life Science Ventures, SLS Invest, InnovationsKapital, Inventure Capital, and Oestjysk Innovation. For more information, please visit www.actionpharma.com

companyNews - 6 June, 2010 - Santaris: Santaris Pharma A/S Receives Red Herring Top 100 Europe Award

2010-06-11 11:07:17

“Choosing the companies with the strongest potential was by no means a small feat,” said Alex Vieux, publisher and CEO of Red Herring. “After rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across Europe to the Top 100 Winners. We believe Santaris Pharma A/S embodies the vision, drive and innovation that define a successful entrepreneurial venture. Santaris Pharma A/S should be proud of its accomplishment, as the competition was very strong.” Red Herring’s Top 100 Europe list has become a mark of distinction for identifying promising new companies and entrepreneurs. Red Herring editors were among the first to recognize that companies such as Facebook, Twitter, Google, Yahoo, Skype, Salesforce.com, YouTube, and eBay would change the way we live and work. “We are pleased to be honored by Red Herring with this award,” said Søren Tulstrup, President and Chief Executive Officer, Santaris Pharma A/S. “Using the broad utility and versatility of our proprietary Locked Nucleic Acid Drug Platform and Drug Discovery Engine, we remain committed to discovering and developing effective RNA-targeted therapies for patients with unmet medical needs for a range of diseases including infectious diseases, inflammatory diseases, metabolic disorders, cancer and rare genetic disorders.” Red Herring’s editorial staff evaluated the companies on both quantitative and qualitative criteria, such as financial performance, technology innovation, management quality, strategy, and market penetration. This assessment of potential is complemented by a review of the track record and standing of startups relative to their sector peers, allowing Red Herring to see past the “buzz” and make the list a valuable instrument of discovery and advocacy for the most promising new business models in Europe. About Santaris Pharma A/S Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the Company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The Company’s research and development activities focus on infectious diseases and metabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, infectious and inflammatory diseases, and rare genetic disorders. The Company has strategic partnerships with Enzon Pharmaceuticals, GlaxoSmithKline, Pfizer and Shire plc. As part of its broad patent estate, the Company holds exclusive worldwide rights to all therapeutic uses of LNAs. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States. Please visit www.santaris.com for more information. Media Relations Contact: Navjot Rai Corporate Communications Santaris Pharma a/s 12626 High Bluff Drive, Suite 440 San Diego CA 92130 USA navjot.rai@santaris.com +1 858 764 7064

companyNews - 4 June, 2010 - Projectplace: Projectplace International Appoints Schwartz Communications as New PR Agency

2010-06-10 16:28:05

Stockholm, June 4, 2010 - Swedish online service Projectplace today announced the appointment of Schwartz Communications as their choice of public relations agency in Sweden, UK and strategically for Europe. Together with Schwartz, Projectplace is aiming at strengthening the company’s brand as well as increasing its market share across Europe. "Projectplace has great ambitions for the European market and is keen to further strengthen its position as a leader in online collaboration,” said Anna Ålenius Mathson, International PR Manager at Projectplace. “We needed an agency that could bring our brand across all Europe. Further, we were looking for a PR agency with a passion for IT, B2B and collaboration in the Cloud. In Schwartz, we have found a great partner within both corporate and product PR, media relations and, for us very evident, non-traditional channels such as social media.” Projectplace International provides Europe's leading project collaboration tool on the web and operates from offices in Sweden (HQ), also handling the UK market, the Netherlands, Germany, Norway and Denmark. From January 2010, the company has implemented an International PR strategy which requires a PR agency with international focus, such as Schwartz Communications. Heading up PR for Projectplace is Kristina Ebenius, Managing Director Europe at Schwartz Communications. The team at Schwartz also includes several PR professionals with expertise in the Swedish, UK and the European markets. “We are excited to have the opportunity to work with the leader in the field for online collaboration on such an ambitious PR strategy,” said Kristina Ebenius, Managing Director Europe at Schwartz Communications. “Schwartz has a longstanding track record in supporting innovative and fast growing companies with PR and we are looking forward to bring our experience and competence into this collaboration with Projectplace.” About Projectplace Since its foundation in 1998, Projectplace has defined projects as social systems and based on this insight designed a software-as-a-service tool for project management. While most other suppliers of project management tools concentrate on supporting detailed work planning in complex systems, Projectplace focuses on transparent communication within the project and with its stakeholders. Projectplace strongly believes that the key to successful projects is to help people share information and manage their commitments. Furthermore the mobile application Projectplace for iPhone empowers project collaboration and communication on the go. International Media Contact: Anna Ålenius Mathson International PR Manager +46 708 930246 anna.alenius.mathson@projectplace.com Press room for media: http://www.mynewsdesk.com/uk/pressroom/projectplace_international For more information about Schwartz Communications please visit www.schwartzcomm.com Today with 550 000 users, Projectplace International has developed and provided Europe's leading web tool for project collaboration since 1998. The company, with about 120 employees is based in Stockholm, Sweden, with local offices in Norway, Denmark, Germany, and the Netherlands. Please visit us at www.projectplace.com

companyNews - 3 June, 2010 - Action Pharma: ACTION PHARMA COMPLETES EUR 5 MILLION FINANCING ROUND TO ADVANCE ITS LEAD PROJECT AP214

2010-06-10 16:09:09

AP214 is being developed for the protection of acute kidney injury in patients undergoing cardiac surgery under cardiopulmonary bypass as its lead indication. Interim phase 2a efficacy and safety data are expected by the end of June 2010. “The recent financing round shows strong continued support from our current shareholders. Further, the additional financing brings the Company into a strong position to execute on the coming key trials for AP214”, says Ingelise Saunders, CEO of Action Pharma. There following current shareholders of Action Pharma participated in the above financing round: Sunstone Capital, Global Life Science Ventures, SLS Invest and InnovationsKapital. For further information, please contact: Ingelise Saunders CEO, Action Pharma A/S Dronninggaards Allé 136 DK-2840 Holte Denmark ils@actionpharma.com +45 2020 3687 About Action Pharma A/S Action Pharma is a privately owned Danish biotech company. Action Pharma develops novel drug candidates targeting melanocortin receptors and bring these to the stage of clinical proof of concept for subsequent partnering. The drug candidates are first in new drug classes and exploit novel mode of action profiles with an efficacy that is superior compared to compounds currently on the market. Action Pharma has a pipeline of several patent protected, in-house developed, drug candidates. Two drug candidates are currently in clinical development, AP1030 (completed phase IB) and AP214 (in phase II), and two drug candidates in late preclinical development. The Action Pharma team has significant scientific expertise and has published more than 400 scientific papers. AP214 is developed to prevent post-surgical kidney injury after major thoracic surgery. AP214 is currently being tested in a phase II clinical trial investigating the effect of AP214 on organ protection in patients undergoing cardiac surgery, who are at increased risk of kidney injury. Every year, more than 150,000 patients in the USA and in the EU undergo major thoracic surgery. Approximately 10-20% of these patients experience various degrees of kidney injury which again is associated with marked increase in mortality, co-morbidity and prolonged hospitalization. Currently, there is no treatment to prevent or treat kidney injury associated with major surgery. Thus there is a major unmet medical need. AP214 mediates its potent effect via the type 1 and type 3 melanocortin receptors. Results from a phase II US clinical trial, from a phase IB trial in human volunteers subjected to LPS-induced inflammation, and initial results from an ongoing phase II trial show encouraging efficacy, safety and tolerability data for AP214. Action Pharma’s proprietary small molecule program further includes compounds for treatment of metabolic diseases and/or inflammatory diseases. AP1030 and second generation compounds have potent pre-clinically documented anti-diabetic and anti-obesity effects and AP1030 administered once daily orally for two weeks in obese human volunteers results in positive effects on glucose metabolism. Thus the program has the potential for development of drug candidates that are superior to other anti-diabetics, including GLP-1 analogues, DPP-4 inhibitors and glitazones. Action Pharma develops AP1189 for oral treatment of systemic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel diseases, atopic dermatitis, COPD and others and AP1189 is ready for clinical development. Similarly, AP405 is developed for topical treatment of inflammatory skin diseases, such as atopic dermatitis and is ready for clinical development. Action Pharma has a strong investor base of leading European investors, including Sunstone Capital, Global Life Science Ventures, SLS Invest, InnovationsKapital, Inventure Capital, and Oestjysk Innovation. For more information, please visit www.actionpharma.com

companyNews - 6 May, 2010 - Aepona: BlackBerry Partners Fund Invests in Aepona

2010-06-10 15:59:06

Belfast, UK - 6th May 2010 - Aepona, the software company that enables a new era of profitable collaboration between mobile operators and application providers, today announced that BlackBerry Partners Fund, a Toronto-based global fund focused on applications, services and supporting infrastructure for mobile platforms, has led a new $10M investment round in the company. Existing Aepona investors Amadeus Capital Partners, Polaris Ventures, Innovacom, Nordic Venture Partners and Sutter Hill Ventures also participated in the round. Aepona, whose revenues grew 50% year-on-year from 2008 to 2009 with positive EBITDA, will use the new round of funding to accelerate its commercial growth. It will invest in additional sales and business development resources to take advantage of the market opportunity that the growing global demand for mobile-enabled applications presents for both the company and its mobile operator customers. Aepona provides the software engine that powers the "Network as a Service" (NaaS) business model for mobile operators. With Aepona's solution, a mobile operator can monetise important assets and functionality within its network - such as billing, location, messaging and voice communications - to open up new revenue opportunities. It can expose and share these assets as Web Service APIs, for third-party application developers, enterprises and media companies to incorporate into new and existing mobile-enabled applications. Aepona is a market leader in the NaaS marketplace through its deployments with more than 20 Tier One mobile operators around the world, together with its pioneering work on the GSM Association’s OneAPI initiative and the launch of the Canadian OneAPI commercial service, which is at the forefront of the Mobile Cloud Computing market. Commenting on its decision to invest in Aepona, Marc Faucher, Partner at BlackBerry Partners Fund said, "Aepona's proposition is constructively aligned with the strategic goals of mobile operators, and the company is ideally positioned to capitalize on the major trends that are shaping the future of the mobile industry." Among these key trends are:

Mobile operators looking for ways to re-assert themselves in the applications value chain to address increasing competition from web-based service providers.
The proliferation of high-end smartphones enabling a new generation of applications and services that combine advanced device functionality with core mobile network functionality, creating significant additional value for the end-user compared with the device-only applications that are prevalent today.
The arrival of Cloud Computing into the mobile domain meaning that application providers can now quickly and easily access mobile network capabilities across multiple operators. This reduces market fragmentation and is vital for driving mass adoption of applications on a global scale.

"Aepona's solution directly addresses these trends, and it's for this reason that BlackBerry Partners Funds believes the company is poised for significant growth. We look forward to working with Aepona, and providing insight and support that will help the company realise its full potential in the mobile eco-system," continues Faucher. "We are delighted to welcome BlackBerry Partners Fund on board as a new investor in Aepona," said Al Snyder, CEO of Aepona. "The Fund shares our vision for the future of the mobile industry – one in which mobile operators can adopt a two-sided business model, delivering differentiated, network-enabled applications through their retail channels as well as directly monetizing their network and billing assets to open up new wholesale revenue opportunities from the Mobile Cloud. We especially look forward to leveraging the relationships that BlackBerry Partners Fund shares with the handset and application developer communities, to develop new propositions that combine the unique capabilities of the mobile device with the power of the mobile network." About Aepona Aepona provides products and services to Telcos globally, enabling them to adopt the emerging Network as a Service (NaaS) business model and unleash the full power of their network assets. With NaaS, Telcos can profit from the current trend towards Mobile Cloud Computing by publishing and monetizing their assets as Web-based APIs towards Enterprises, Web-Based Service Providers and Application Developers. Aepona's products are used by operators globally to power 1.2 billion monthly transactions and deliver $1 billion annual revenues to operators, application and content providers. Aepona is also the technology provider for the GSMA's OneAPI initiative. For more information, visit www.aepona.com About BlackBerry Partners Fund The BlackBerry Partners Fund™ is designed to deliver superior returns on the compelling investment opportunity in applications, services and supporting infrastructure for the BlackBerry® and other mobile platforms. The Fund's mandate is based on the premise that in the future smartphones will be powerful portable computers for use at home, work, and leisure. The Fund invests in companies developing applications that make smartphones a compelling platform for media, commerce, enterprise, entertainment, and lifestyle applications. The Fund is global in scope and will consider all stages of development. For further information visit: www.blackberrypartnersfund.com For further information contact: For Aepona: Michael Crossey Vice President Marketing, Aepona michael.crossey@aepona.com +44 7734 318210 www.aepona.com For BlackBerry Partners Fund: Jodi Echakowitz Echo Communications +1 (905) 709-9600 mobile: +1 (416) 271-7250 jodi@echo-communications.com

companyNews - 20 May, 2010 - Ludesi: Bio-Rad Introduces REDFIN 2-D Analysis Service to Simplify 2-D Gel Analysis

2010-06-10 14:31:33

The REDFIN 2-D analysis service uses a downloadable software interface that researchers can use to quickly import their 2-D gel images. Then a team of REDFIN 2-D gel analysis experts analyze the uploaded images and return the results to the researcher. With REDFIN 2-D analysis service, researchers no longer need to perform the tedious tasks of manually counting and aligning spots on their gels. REDFIN helps researchers who are getting started with 2-D analysis, providing them with guidance through the process as well as giving additional confidence in their final results. "REDFIN 2-D analysis service will save 2-D gel electrophoresis users time by offering them an easy-to-use solution that yields faster results and peace of mind by having the analysis performed by experts," said Katy McGirr, Product Manager, Lab Separations Division. "And with the ‘pay-as-you-go’ nature of the service, REDFIN analysis is a low-risk way for researchers to get started in 2-D gel experiments." The image analysis by REDFIN professionals consists of spot detection and segmentation, and spot matching, as well as quantification and normalization. The service ensures that the spot detection process is objective and unbiased and offers consistently reproducible results across multiple experiments. The key benefits of the REDFIN 2-D service are:

An easy-to-use and navigate software interface
Versatility of using any 2-D stain, including DIGE and protein-specific stains
Convenience of performing advanced statistical calculations on the results with REDFIN software
Added data security: results are password protected and backed up by the REDFIN service
An easy way for researchers to share information via email

The REDFIN 2-D analysis service is a credit-based system. Researchers are able to pay as they go or pre-purchase credits for future projects. For most projects, researchers are able to choose the Basic service level (2 credits per gel) or they can select the Pro level (10 credits per gel) to remove streaks and artifacts and improve quality assurance for spot detection and matching. For more information about the REDFIN 2-D analysis service, please visit www.expressionproteomics.com/redfin The REDFIN 2-D analysis service is available through a partnership between Bio-Rad and Ludesi Corporation, a global bioinformatics company. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, and major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,800 people globally and had revenues of nearly $1.8 billion in 2009. For more information, visit www.bio-rad.com For more information, contact: Katy McGirr, PhD Bio-Rad Laboratories, Inc. +1 510-741-6548 Katy_McGirr@bio-rad.com Ken Li Chempetitive Group +1 312-997-2436 kli@chempetitive.com

companyNews - 18 May, 2010 - Silecs: Silecs Appoints VP of Sales

2010-06-10 12:34:21

Mr. Wai-Meng Chik has over 15 years experience in the semiconductor industry. Prior to joining Silecs, he was Regional Technical Sales Director at Dow Chemical Electronic Materials responsible for Photo-chemicals “Silecs is entering a new growth phase, with innovative silicon-based polymer offerings for the emerging advanced packaging and CMOS image sensor applications. Silecs has kept setting new sales records in the recent months. Wai Meng, with his extensive industry knowledge and experience, will help Silecs to further accelerate our growth.” Said CEO Mr. Kok-Whee Teo. Mr. Chik started his career in the process equipment engineering and had participated in the start- up of 2 wafer fabrication plants in South East Asia as a pioneering engineering member. He has also assumed various senior roles in sales and business management of key production and metrology equipment used in front-end wafer processing. Mr. Chik holds a Bachelor Degree in Electrical & Electronics Engineering and an MBA. Mr. Chik will lead the global sales team, especially focusing in developing fast emerging segments in Advanced Packaging and Semiconductor applications. About Silecs Silecs is a global developer and manufacturer of silicon-oxygen polymers. These precision dielectrics and coatings enable production of ever-denser microelectronic devices as Moore’s Law progresses. Using nano-particles, the company tailors product performance to the most critical and demanding customer requirements, ranging from temperature to transparency. Its principal locations and customer partnerships include: China-Taiwan, Finland, Japan, Korea, Singapore, and the US. The company can be found at www.silecs.com

companyNews - 10 May, 2010 - Ignis: Ignis signs optical splitter contract with major European system house

2010-06-10 12:08:32

The customer will deploy Ignis' optical splitters in PON systems for access and mobile networks in various regions around the world. Ignis is also discussing supply of splitter chips to the customer's own splitter module packaging unit in China, which is also being explored as a possible contract manufacturer for Ignis. The agreement adds to a series of new optical splitter contracts signed earlier in the year. In total, Ignis signed contracts for active and passive components worth USD 18-19 million (NOK 103-110 million) in the first quarter of 2010. For further information, please contact: Thomas Ramm Ignis ASA Chief Executive Officer +47 913 70 795 thomas.ramm@ignis.com Walker Kinman Ignis ASA Chief Financial Officer +46 70 722 6513 walker.kinman@ignis.com www.ignis.com This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

innkapNews - 24 March, 2010 - InnovationsKapital: InnKap 4 Partners LP invests SEK 29.5 million in Gammadata AB to acquire shares and establish a long-term relationship

2010-06-10 09:47:43

Gammadata Group is established as a leader in the three areas of operations and serve customers across the globe. “We are very pleased to have InnKap 4 Partners as a new owner. We expect InnKap to support our promising plans, and to help us to take Gammadata forward”, says Jan Edhäll, CEO at Gammadata. InnovationsKapital invests in Nordic high-tech companies with strong growth. “Gammadata is a very interesting company with a unique product offering based on Nobel price winning technology. The company has a strong management team and we see this as a great opportunity to invest in a company with good growth, profitability and cash generation”, says Martin Falkevall, responsible for InnovationsKapital’s investment in Gammadata. For more information, please contact: Jan Edhäll CEO, Gammadata +46 18 480 58 00 www.gammadata.se Martin Falkevall Investment Director, InnovationsKapital +46 8 545 014 90 mf@innkap.se www.innkap.se InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences. To date, over 65 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

companyNews - 4 May, 2010 - UpFront: DSM Biologics to Acquire Rhobust(TM) Technology from Upfront Chromatography A/S

2010-05-10 17:47:37

PARSIPPANY, N.J., May 4 /PRNewswire/ -- DSM Biologics, a business unit of DSM Pharmaceutical products, today announced it has reached an agreement for the acquisition of the assets and associated business of the Rhobust™ technology from Upfront Chromatography A/S (Denmark) for pharmaceutical and other applications. As a result of the acquisition, DSM Biologics will gain all rights for the commercialization of the Rhobust™ technology in various fields, including the pharma industry. The Rhobust™ technology will lead to further innovation in the downstream processing for the manufacturing of recombinant proteins and antibodies. DSM Biologics will continue to support all existing clients for this technology. The parties have agreed to not disclose financial details. Karen King, President of DSM Biologics commented: "The acquisition of the Rhobust™ technology is an important addition to the portfolio of DSM Biologics," a provider of technologies for the optimization of biopharmaceutical manufacturing processes, in addition to world-class contract manufacturing services. "The Rhobust™ technology combined with DSM's proprietary XD® technology will provide an integral package combining high titer, high yield processing with efficient downstream processing leading to lower manufacturing costs." King added. The Rhobust™ technology has proven its ability to perform with high titer and high density cell culture processes. Compared to a conventional harvest approach, the number of unit operations is reduced. The cells are separated in one step while capturing the protein/antibody of interest. In the expanded bed adsorption chromatography (EBA) the cell suspension passes through the column and the product is adsorbed either on Protein A or on mixed mode ligand beads. This leads to less handling and shorter process times. Rolf Douwenga, Vice President, Global Technology of DSM Biologics said: "DSM Biologics develops new technologies to meet the challenges of future biopharmaceutical manufacturing. Our proprietary XD® technology was a first step in yielding high density cell cultures. We have achieved up to 200million cells/ml and titers up to 27 g/L for antibodies. This brings a real challenge to the downstream process; conventional process technology is of limited use here. With the Rhobust™ technology we can address this issue, and we are constantly broadening our technology portfolio for an even more effective biomanufacturing process." About DSM Biologics and XD® Technology DSM Biologics, a business unit of DSM Pharmaceutical Products, is a global provider of manufacturing technology and services to the biopharmaceutical industry. In addition to the offering of world-class biopharmaceutical manufacturing services, DSM Biologics provides and develops technologies relevant for optimized mammalian cell culture processes. Examples are the proprietary XD® Technology for use with mammalian cell lines. The "XD process" leads to very high cell densities within the bioreactor, which result in maximum productivity using readily available equipment. DSM's manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market. More information: www.dsmbiologics.com About Rhobust™ Technology The Rhobust™ technology is an invention by Upfront patented around the world in different patent families. The Rhobust™ technology consists of cross linked Tungsten Carbide - agarose beads to increase the density of the particles. This increased density leads to stable expanded bed adsorption chromatography (EBA). About Upfront Chromatography Upfront Chromatography A/S develops and manufactures innovative products and technologies for extraction and recovery of biomolecules, macromolecular complexes, and even living cells, directly from bioreactors and industrial side-streams. For customized separation services, Upfront offers access its universal process platform combined with extensive technical and regulatory support. From a feasibility study to commissioning of the final installation, Upfront works with its customers to develop adsorbents, ligand chemistry, columns and other hardware to optimise process performance. Upfront is currently developing the world's largest chromatography system. Upfront's research, development and ISO9001-compliant manufacturing facility is situated in Copenhagen, Denmark. DSM Pharmaceutical Products DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: www.dsmpharmaceuticalproducts.com DSM - the Life Sciences and Materials Sciences Company Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM has annual net sales of EUR 7.7 billion and employs some 22,738 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com XD® is a registered trademark of DSM N.V. Rhobust™ is a trademark of DSM N.V. DSM Forward-looking statements This press release contains forward-looking statements that involve inherent risks and uncertainties. These statements are based on current expectations, estimates and projections of the management of DSM and information currently available. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that their expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release. For more information: Rolf Douwenga Vice President, Research and Development DSM Biologics +1-973-257-8220 Rolf.Douwenga@dsm.com Spencer Reynolds Director, New Business Development DSM Biologics +1-973-257-8056 Spencer.Reynolds@dsm.com

companyNews - 26 April, 2010 - Santaris Pharma: Santaris Pharma A/S advances RNA-targeted drug development candidate against PCSK9, an important new target for the treatment of high cholesterol

2010-05-10 12:04:54

Santaris Pharma A/S selects lead research compound SPC5001 targeting PCSK9 to advance into drug development for the treatment of high cholesterol
PCSK9, an important new target, is a protein involved in regulating LDL or “bad” cholesterol in the blood– a major risk factor for coronary heart disease, heart attack and stroke
Preclinical data presented at PCSK9 Conference show SPC5001 provided potent, specific and long-lasting inhibition of PCSK9 and lowered LDL cholesterol in primates by up to 74%
Versatility and broad utility of Santaris Pharma A/S LNA Drug Platform and Drug Discovery Engine critical in developing effective RNA-targeted therapies for a range of diseases

Hoersholm, Denmark/San Diego, California, April 26, 2010 — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months. High cholesterol is a major risk factor for coronary heart disease, heart attack and stroke. According to the World Health Organization, high cholesterol is estimated to cause 18% of strokes and 56% of heart disease, globally and amounts to approximately 4.4 million deaths and 40.4 million disability-adjusted life years[1]. Santaris Pharma A/S presented preclinical data on SPC5001 last month at the PCSK9 Conference “From gene to therapeutics” in Nantes, France where many top pharmaceutical companies gathered to discuss efforts to develop therapies aimed at inhibiting the important new target PCSK9, a protein involved in regulating LDL (low-density lipoprotein) or “bad” cholesterol in the blood. Data presented by Santaris Pharma A/S scientists showed that SPC5001 provided potent, specific and long-lasting inhibition of PCSK9 and lowered mean LDL cholesterol by 50% in non-human primates with a sustained reduction of 74% in the highest responder. SPC5001 did not change HDL (high-density lipoprotein) levels or the “good” cholesterol in the blood[2]. The preclinical data suggest that SPC5001 has the potential to provide patients with a new treatment option in managing their cholesterol levels. “There is a lot of interest in PCSK9 as an exciting new target for the treatment of high cholesterol and having demonstrated that SPC5001 effectively lowers LDL or the “bad” cholesterol in preclinical studies, we are quickly moving forward with plans to advance SPC5001 into clinical studies as a potential new treatment to help patients better manage the risks of cardiovascular diseases,” said Henrik Ørum, PhD, Vice President and Chief Scientific Officer of Santaris Pharma A/S. “SPC5001 is a testament to the efficiency of our LNA Drug Platform and Drug Discovery Engine as we discovered, optimized and advanced SPC5001 into preclinical development in just 18 months.” The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combines the Company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates for a range of diseases including metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders. “In addition to advancing SPC5001 into drug development for the treatment of high cholesterol, we remain on track to begin Phase 2 clinical trials of miravirsen (SPC3649) in patients with Hepatitis C in the second half of this year,” “In our internal programs and partnered programs, the versatility and broad utility of Santaris Pharma A/S LNA Drug Platform and Drug Discovery Engine continues to be critical in developing effective RNA-targeted therapies with high affinity, target specificity and remarkable potency for a range of diseases.” SPC5001 adds to the portfolio of Santaris Pharma A/S drugs in development, including its most advanced compound miravirsen, the International Nonproprietary Name (INN) or generic name for the compound formerly known as SPC3649. Miravirsen, the first microRNA-targeted drug to enter human clinical trials, is a specific inhibitor of miR-122, a liver-specific microRNA that the Hepatitis C virus requires for replication. Unlike Hepatitis C therapies that directly target the virus, miravirsen works by removing a “helper” molecule (miR-122) that the virus needs in order to make new copies. Miravirsen is being studied in a Phase 1 trial multiple-ascending dose study in healthy volunteers and a Phase 2 study in patients infected with Hepatitis C is expected to begin in the second half of 2010. Santaris Pharma A/S also has a broad range of drug discovery and development programs with its partners: Shire plc (lead candidates against up to five targets for rare genetic disorders), Pfizer (lead candidates against up to ten targets), GlaxoSmithKline (options to drug candidates from up to four viral disease programs) and Enzon Pharmaceuticals (lead candidates against eight cancer targets successfully delivered). About Locked Nucleic Acid (LNA) Drug Platform The LNA Drug Platform utilizing Santaris Pharma A/S proprietary LNA chemistry provides the key to delivering on the promise of RNA-targeted therapies today by addressing these concerns and overcoming the limitations of earlier antisense and siRNA technologies to deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The unique combination of small size and very high affinity, which is only achievable with LNA-based drugs, allows this new class of drugs to potently and specifically inhibit RNA-targets in many different tissues without the need for complex delivery vehicles. LNA-based drugs are a promising new type of therapy that enables scientists to develop drugs to attack previously inaccessible clinical pathways. The most important features of LNA-based drugs include excellent specificity, providing optimal targeting; increased affinity to targets providing improved potency, and strong pharmacology upon systemic delivery without complicated delivery vehicles. About Santaris Pharma A/S Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the Company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The Company’s research and development activities focus on infectious diseases and metabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, infectious and inflammatory diseases, and rare genetic disorders. The Company has strategic partnerships with Enzon Pharmaceuticals, GlaxoSmithKline, Pfizer and Shire plc. As part of its broad patent estate, the Company holds exclusive worldwide rights to all therapeutic uses of LNAs. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States. Please visit www.santaris.com for more information. Media Contact: Navjot Rai Santaris Pharma A/S Office: + 1 858 764 7064 ext. 206 Cell: +1 619 723 5450 navjot.rai@santaris.com [1] World Health Organization - http://www.who.int/healthinfo/statistics/bod_cerebrovasculardiseasestroke.pdf [2] Oral and poster presentation PCSK9 Conference, Locked Nucleic Acid antisense oligonucleotide inhibition of PCSK9, March 11, 2010

companyNews - 8 April, 2010 - BoneSupport: BONESUPPORT hires four top names in sales and marketing

2010-05-10 11:53:19

As Chief Commercial Officer, Vikram Johri will build a new marketing and sales division. His most recent position was Vice President Marketing EMEA at Wright Medical in the Netherlands. Inès X. Wanderer will serve as Vice President Sales Central Europe (Germany, Austria and Switzerland). She was employed most recently by Medtronic GmbH in Germany. Adrian Beere comes from Zimmer Spine in the UK and has been appointed to Vice President Sales Western Europe. Linda Butcher joins as Vice President Marketing from Boston Scientific where she was responsible for Global Marketing. Hiring top marketing and sales personnel is integral to upgrading BONESUPPORT’s commercial organization as it launches its CERAMENT™ Spine Support and CERAMENT™ Bone Void Filler products, which were approved by the EU for treatment of spinal fractures in 2008 and 2009. 'The success and far-reaching sales and marketing experience that Vikram, Inès, Linda and Adrian have, strengthens us as we take the next steps in our growth and development,' says BONESUPPORT President Fredrik Lindberg. 'We are in an expansive phase, and high performance individuals will ensure that our organization is up to the challenge.' Long experience in the medical technology industry Having worked for Wright Medical, Boston Scientific International, Uromed and Mitek, Mr. Johri has long, in-depth experience of the medical technology industry. He will continue to be based in the Netherlands. 'I am very pleased to have the opportunity to work for BONESUPPORT, which is at an exciting stage of its development,' says Mr. Johri. 'The company offers platform technology with great commercial potential. I look forward to building the new sales and marketing organization in accordance with its expansion plans. Being part of a Swedish organization that has such a fine reputation and position in the international market is a privilege.' For additional information, feel free to call: Fredrik Lindberg, President +46 708 86 53 70 Press photos are available at www.bonesupport.com BONESUPPORT BONESUPPORT AB is an innovative Swedish medical technology company that specializes in the development of high-tech solutions for the treatment of osteoporotic fractures, herniated discs and other conditions. Founded in 1999, the company has over 30 employees and is headquartered at Ideon Science Park in Lund, Sweden. BONESUPPORT has subsidiaries in the United States, Netherlands and Germany. Its two main trademarks are CERAMENT™ and ULTRAZONIX®.

companyNews - 21 April, 2010 - Projectplace: Projectplace launches new features supporting social project management

2010-05-10 11:48:38

The new social features are based on the insights that Projectplace has gained over the past 12 years on what lies at the heart of a successful project. One of the main factors is that both commitment and creativity increase in projects with clear and open communication among project members. - “Projects that offer members more freedom and enable them to interact with one another and discuss matters openly, breed an atmosphere of trust and confidence,” says Mattias Hällström, Projectplace founder. “With an open forum it’s much easier to spot and correct a situation or adapt to change," he concludes. With the new social Project Overview and the Project Wall, project members can quickly and easily exchange comments on the project’s objectives, discuss and develop new ideas, share documents, images and videos. - “It works a bit like Facebook,” explains Product Owner, Ellen Ekerling. “When Facebook is focused on the sharing status, comments, photos and movies about private matters, Projectplace focuses on sharing work material within projects, such as thoughts about the project, new ideas, planning etc”. The new social Project Overview provides a quick and clear visual overview of the current situation of a project along with the objectives and a timeline with the key decision points. It also contains an image map of all the project members as well as information about upcoming events. The beta version of the Project Overview was launched for testing on April 20th. Comments and ideas collected from customers will shape the final design and functionality of the Project Overview, real launch planned to summer 2010. Read more and test the feature here: www.projectplace.com/project-wall/ * In May 2009, Projectplace launched Projectplace for iPhone with several social functions. With the application you can handle your project, read documents, contact and interact with team members wherever you are. ** Read more about Social project management here: http://en.wikipedia.org/wiki/Project_management_2.0 PR & Information: Anna Ålenius Mathson, International PR Manager, Projectplace International +46 708 93 46 anna.alenius.mathson@projectplace.com Today with 540 000 users, Projectplace International has developed and provided Europe's leading web tool for project collaboration since 1998. The company, with about 120 employees ,is based in Stockholm, Sweden, with local offices in Norway, Denmark, Germany, and the Netherlands. www.projectplace.com

companyNews - 9 April, 2010 - Jolife: LUCAS™2 wins the US Medical Design Excellence Award

2010-05-10 11:21:02

Jolife AB today announced that LUCAS™2 Chest Compression System has received a 2010 Medical Design Excellence Award in the US. The LUCAS™2, which is the latest generation launched during 2009, is a medical device developed and manufactured by Jolife AB. The device is used by emergency care providers to help save sudden cardiac arrest patients by providing effective, consistent and uninterrupted chest compressions to circulate the patient’s blood. The Medical Design Excellence Awards competition (www.MDEAwards.com) is organized and presented by Canon Communications LLC (Los Angeles, US) and is the only awards program that exclusively recognizes contributions and advances in the design of medical products. Entries are evaluated on the basis of their design and engineering features, including innovative use of materials, user-related functions that improve healthcare delivery and change traditional medical attitudes or practices, features that provide enhanced benefits to the patient, and the ability of the product development team to overcome design and engineering challenges so that the product meets its clinical objectives. A comprehensive review of the entries was performed by an impartial, multidisciplinary panel of third-party jurors with expertise in biomedical engineering, human factors, industrial design, medicine, and diagnostics. “We are honored by this recognition of the LUCAS™2 device by the MDEA judges, “ said Erik von Schenck, CEO of Jolife AB. “In emergency care, where time to therapy is critical, it is important to offer a product that is intuitive, quick to apply and has a practical design that can be used in most situations. This has been the goal when developing LUCAS 2.” The 2010 Medical Design Excellence Award winners will be honored at a presentation ceremony on Wednesday, June 9, 2010 in New York City’s Jacob K. Javits convention Center, in conjunction with the Medical Design & Manufacturing (MD&M) East Conference and Exposition (www.MDMEast.com), June 8-10, 2010. Gold and silver award recipients will be announced at this time. About LUCAS CPR LUCAS Chest Compression System is an easy-to-use and lightweight device that provides quality chest compressions according to the European Resuscitation Council and American Heart Association Guidelines for CPR (cardiopulmonary resuscitation). It assists rescuers in maintaining vital blood circulation in cardiac arrest patients. LUCAS is simple to use, applied within seconds and feasible for use in a majority of cardiac arrest patients. LUCAS is available in an electrically driven version (LUCAS 2) and a pneumatically driven (LUCAS 1). An estimated 25 000 patients have been treated with LUCAS so far. The mechanical CPR device has shown to increase operational efficacy and to improve the opportunities to save cardiac arrest patients. About Jolife AB Jolife AB, founded in 2000, develops and manufactures the LUCAS Chest Compression System. Jolife works closely with leading physicians, nurses, paramedics and first responders and is committed to research and development in order to continue to offer innovative products. The LUCAS Chest Compression Systems are sold in 34 countries around the world. Based in Lund in southern Sweden, Jolife markets its products through an exclusive global distribution agreement with Physio-Control, Inc., a division of Medtronic Inc. – except in Sweden, Norway and Finland, where Jolife sells directly. Further information: Erik von Schenck, CEO, JOLIFE +46 46 286 5002 evs@jolife.com Or Sara Lindroth, Marketing Director, JOLIFE +46 46 286 5024 sara.lindroth@jolife.com Jolife AB Scheelevägen 17 223 70 Lund Sweden +46 46 286 5000 www.jolife.com www.lucas-cpr.com

innkapNews - 23 April, 2010 - InnovationsKapital: The best investment of all time - InnovationsKapital and CapMan (Swedestart) for Altitun AB

2010-05-06 16:07:54

A new prize is instituted specifically for SVCAs 25th anniversary rewarding a private equity firm that has made an exceptionally successful investment. Motivation: An investment in a small seed company with negative cash flow came to be a jackpot for the entrepreneurs and investors when the company after a great journey got acquired by an industrial partner. The active ownership by private equity firms, combined with the portfolio company's unique high-tech competence came to be a success story that became a symbol of good entrepreneurship, innovation and commercialization. At the acquisition the VCs received incredible 87 times the money. The deal turned out to be glorious also for the Swedish taxpayers having invested in the research in the company. The sale of the company meant tax revenue to the Swedish state of entire SEK 1 billion. For further information, please contact: Staffan Ingeborg, Investment Director, InnovationsKapital +46 70-583 14 34 staffan.ingeborn@innkap.se www.innkap.se InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences. To date, over 65 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

innkapNews - 5 February, 2010 - InnovationsKaptial: Wind River to Add Virtutech Simics Products to Comprehensive Embedded Software Portfolio

2010-02-26 10:23:16

Wind River will sell and support Virtutech’s flagship development platform, Simics, as a stand-alone product and will continue to support all current architectures including ARM, Intel, MIPS and PowerPC. Simics will allow Wind River to offer a market-leading virtual systems development solution in a growing market segment of virtualization and simulation tools for device software development. “The addition of Virtutech’s development platforms to our product line will allow Wind River to offer greater value to customers across the entire product lifecycle and deepen current relationships with our broad set of silicon partners,” said Ken Klein, president, Wind River. “Time-to-market remains the single most challenging issue that sophisticated electronic equipment manufacturers need to address and ultimately control in order to remain competitive. With the addition of the Simics products, Wind River adds a key solution to further help customers improve time-to-market, as system complexity and ever more stringent demands upon overall system quality rapidly increase.” “Through our long-standing partnership with Wind River, it became evident that both companies shared a vision of how we can help the electronic systems market rethink how it goes about complex product development by deploying virtual platforms,” said John Lambert, CEO, Virtutech. “Time and again, Virtutech has helped customers and partners improve time-to-market by enabling the full sweep of systems development activities to take place on a virtual platform, freeing them up to apply new and innovative ways of running systems development projects. By combining with Wind River, we now have the opportunity to dramatically accelerate the spread of this key market trend and to bring the benefits of virtual platforms to a broader audience.” Simics provides binary-compatible hardware simulations that operate completely within a virtualized environment running on standard laptop or desktop PCs. This strategy allows OEMs to undertake critical software development activities on a virtual platform, independently of any hardware development schedules, semiconductor availability constraints or other limitations. This also allows semiconductor manufacturers to redefine complex system-on-chip development with greater ecosystem support and customer engagement. Virtutech therefore enables customers to manage complexity, drive improved quality and achieve higher productivity, all while lowering capital expenditure and shortening total development time. Acquired by Intel last year, Wind River develops operating systems, middleware (software found between an OS and software application), and software design tools for a variety of embedded computing systems. Its main products include VxWorks, the market-leading proprietary and multicore-ready real-time operating system, and commercial-grade Linux software platforms. The company also provides design services and software expertise, including custom-built solutions, development tools and device testing products. With thousands of customers, Wind River technology is relied upon by most major computer and networking communications companies, and is used by corporations and government agencies such as Alcatel-Lucent, BMW, Boeing, Bombardier Transportation, Mitsubishi, Motorola, NASA, Sony, Verizon and many more. Intel’s acquisition of privately-held Virtutech is expected to be completed this quarter. Terms of the deal are not being disclosed. About Virtutech Virtutech, Inc. is the leader in product development process improvement through virtualized systems development (VSD). Virtutech Simics® allows for a revolutionary change in the product development process at a full system level rather than a component level and is a commercial solution that uniquely delivers the four most important criteria for successful deployment of hardware virtualization in the electronics equipment development process: speed, scalability, model availability, and control. Simics customers report reduced time to market, better project risk management, lower capital expenditure, product development cost and maintenance as well as increased quality and individual productivity. Virtutech serves the needs of the world’s leading OEMs in the high-performance computing, aerospace and defense, telecommunications, networking and semiconductor industries. Customers include Cisco, Ericsson, Freescale Semiconductor, GE Avionics, Honeywell, IBM, Lockheed Martin, Nortel and Northrop Grumman. Virtutech is an active participant in organizations to drive adoption of VSD such as ARM Connected Community, Eclipse.org, IBM PartnerWorld, Multicore Association, Power.org, OSCI and Spirit Consortium. For more information, visit www.virtutech.com About Wind River Wind River, a wholly owned subsidiary of Intel Corporation (NASDAQ: INTC), is a world leader in embedded and mobile software. Wind River has been pioneering computing inside embedded devices since 1981 and its technology is found in more than 500 million products. Wind River is headquartered in Alameda, Calif. with offices in more than 15 countries. To learn more, visit Wind River at www.windriver.com or blogs.windriver.com CONTACTS Bryan Thomas Wind River Tel: +1 510-749-2414 bryan.thomas@windriver.com

innkapNews - 18 December, 2009 - InnovationsKapital: Microdata raises 10 million SEK to fund international expansion

2010-01-18 16:39:07

Microdata Telecom Innovation AB is raising 10 million SEK from venture capital firm InnovationsKapital and from existing shareholders through an equity issuance. Microdata Telecom is currently expanding internationally to address a rapidly growing global market for Microdata Advanced Site Solutions ( MASS™ ) in the mobile infrastructure market. Through this equity infusion, we are able to further expand our marketing and sales internationally with our portfolio of state of the art radio products within Advanced Site Solutions says Mats Gustavsson, CEO and co-founder of Microdata. We believe that InnovationsKapital will be a valuable partner as we grow the company. Microdata is led by an impressive team with solid experience both from the industry and from building companies, says Martin Falkevall from InnovationsKapital. We have been impressed by their early customer traction and are looking forward to an exciting journey together with the company in the coming years For further information, please contact: Mats Gustavsson CEO Microdata Telecom Innovation AB +46 708 15 69 25 mats.gustavsson@microdata.se Martin Falkevall InnovationsKapital Nordic Advisor AB +46 8 54 50 14 90 martin.falkevall@innkap.se Linda Höljö InnovationsKapital Nordic Advisor AB +46 8 54 50 14 90 linda.holjo@innkap.se Microdata Telecom Innovation AB offers cost effective radio solutions to OEMs and Network Operators, in order to improve radio coverage, capacity and quality of mobile communications. The company has offices in Täby, Sweden and in India. For further information, please visit: www.microdata.se InnovationsKapital was founded in 1994 as an independent private equity/venture capital firm focused on investments in growth companies. Our investment strategy is to invest in technology companies in the Nordic countries. InnovationsKapital has invested in over 60 companies and Carmen Systems, Formex, Kreatel, Nordnav and Spotfire are some examples of successful exits. InnovationsKapital currently advises four venture funds aggregating over 3 billion SEK (or about 300 million Euro), raised from well renowned Swedish and international institutional investors. For further information about InnovationsKapital, please visit our webpage: www.innkap.se

innkapNews - 8 December, 2009 - InnovationsKapital: Medius is raising external capital to fund international expansion

2009-12-08 09:20:21

Medius, which prior to the equity issuance had been owned by management and personnel, has grown organically and profitably every year since its founding in 2002. The last three years (2006-2008), the company’s revenue has increased by 430% and is on target to reach 90 million SEK (or about 9 million Euro) in 2009. A strategic plan for 2010-2012 includes offering part of the company’s products in non-domestic markets, and in 2012, 40% of revenue is planned to come from markets outside of the company’s home country. Medius is a well established company in Sweden with over 300 customers, including, among others, Saab, Haldex, Stadium, Mekonomen, K-rauta, and The Body Shop. This equity injection gives the company the opportunity to continue its rapid expansion in the rest of the Nordic countries, the Netherlands, Germany, the UK, and in France. Through this equity infusion, we are able to carry out the expansion plans that we have for the upcoming three years. We see an enormous market opportunity for our workflow platform offering, MediusFlow, in markets that we are planning to expand into in the years 2010 through 2012. Given that we in only a matter of a few years have become market leading in Sweden within certain applications – for example support for the purchase to payment process, where support for handling of invoicing has been wildly successful – we are confident that this international expansion will be successful as well, says Per Nordling, CEO and co-founder of Medius. We have been in discussions with a number of venture capital firms, and realized early on that InnovationsKapital was the best partner for Medius at this time. Through their prior investments they have shown good judgment and they take a long term perspective, Per Nordling continues. Medius has all the attributes that we look for in new investments – a great team, a strong and competitive customer offering, and a fast growing market, say Peder Holm and Fredrik Cronqvist from InnovationsKapital. We are looking forward to helping Medius and the existing shareholders in this upcoming expansion. For further information, please contact: Per Nordling CEO Medius AB +46-13-12 16 30 per.nordling@medius.se Peder Holm InnovationsKapital Nordic Advisor AB +46-8-54 50 14 90 peder.holm@innkap.se Fredrik Cronqvist InnovationsKapital Nordic Advisor AB +46-8-54 50 14 90 fredrik.cronqvist@innkap.se Medius aspires to deliver the world‘s best business system support covering all aspects from the requirement setting phase to, and including, the administration phase. This span is dealt with in three business areas: Consulting, ERP, and Workflow. For the Nordic market, Medius works within all three business areas. In the markets outside of the Nordic countries, Medius primarily focuses on the offerings of the Medius workflow business area, i.e. Workflow™. Medius is currently represented in Sweden (headquarters), the Nordic countries, the Netherlands, Germany, the UK, France, United Arab Emirates, and in Poland. Through our global partners we reach organizations all over the world. For further information, please visit: www.medius.se InnovationsKapital was founded in 1994 as an independent private equity/venture capital firm focused on investments in growth companies. Our investment strategy is to invest in technology companies in the Nordic countries. InnovationsKapital has invested in over 60 companies and Carmen Systems, Formex, Kreatel, Nordnav and Spotfire are some examples of successful exits. InnovationsKapital currently advises four venture funds aggregating over 3 billion SEK (or about 300 million Euro), raised from well renowned Swedish and international institutional investors. For further information about InnovationsKapital, please visit our webpage: www.innkap.se

innkapNews - 4 December 2009 - InnovationsKapital: PBM Sweden AB and InnovationsKapital initiate a long-term relation where InnKap 4 Partners LP initially invests SEK 7.5 million.

2009-12-07 15:55:17

Customers are mainly county councils, insurance companies and private companies. ”InnovationsKapital is a serious, long term and stabile investor with a strong track record of helping companies grow and realise their potential”, says the senior consultant Nils Edelstam (M.D.), PBM. PBM is currently based in six cities - Stockholm, Göteborg, Malmö, Gävle, Hudiksvall and Söderhamn. PBM plans to start further business in Sweden and the other Nordic countries. InnovationsKapital invests in young Nordic companies within the Healthcare & Life Sciences and ICT sectors. ”PBM is a very qualified company that continuously delivers excellent and lasting results to its customers. We are convinced that they will grow rapidly in this expansive market”, says Gunnar Fernström being responsible for InnovationsKapital’s investment in PBM. In total InnKap 4 Partners LP will invest up to SEK 19 million in this round of finance. For more information, please contact Tina Nikolaidou, Market Director, PBM, +46 70-569 28 82, www.pbm.se Gunnar Fernström, Investment Director, InnovationsKapital +46 70-312 05 02 gunnar.fernstrom@innkap.se www.innkap.se InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. To date, over 65 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

innkapNews - 30 June 2009 - InnovationsKapital: Projectplace’s new owners reinforces European strategy

2009-07-06 15:02:14

On Friday June 26, 2009, Projectplace International AB, Europe’s leading online project collaboration tool, was acquired by three venture capital companies. The buyers all have prior relationships with the company and good insight and understanding of its business. The ownership change is a step in the company's continued development and strengthens its future opportunities. - “We are already well established as the market leader in Sweden and Norway and are growing rapidly in Germany and the Benelux region. The new ownership provides us the ability to continue strengthening our position in existing markets while expanding in new European markets”, says Pelle Hjortblad, CEO, Projectplace International. Projectplace International’s business has been growing 30% per year the last three years. The turnover amounted to SEK 129 million in 2008. With the new owners on board the company see a strong opportunity for continued rapid expansion through organic growth as well as strategic acquisitions. - “We have had an eye on Projectplace International for a while”, says Anders Grånäs, Via Venture Partners. “When we got the opportunity to complete this deal, it was a very easy decision for us. The process has been fast and all parties agree.” - “Projectplace International is an innovative, well-run company with high development potential”, says Anders Ösund, Investor Growth Capital. “As an existing owner, we have followed the company for many years. With a clear Europe focused strategy, the company has a great opportunity to increase its growth rate further in coming years.” Investor Growth Capital, Via Venture Partners and InnovationsKapital will each own 30% of the company. The remaining 10% will be offered to a number of key employees within the company - “We are very pleased that the company's management and key employees want to invest and thereby take an active part in the company's continued development. We strongly believe that Projectplace has great potential and are very happy that the management clearly feels the same way”, says Magnus Berglind, InnovationsKapital. Contact: Projectplace International, Pelle Hjortblad, CEO, tel. +46 701810110 Investor Growth Capital, Anders Ösund, tel. +46 73 5241824 Via Venture Partners, Anders Grånäs, tel. +46 734441001 InnovationsKapital, Magnus Berglind, tel. +19175820396 Public Relations Projectplace International: Anna Ålenius Mathson, PR Manager Tel: +47 708 93 02 46, email: anna.alenius.mathson@projectplace.com Since 1998, Projectplace International has developed and provided Europe's leading web tool for project collaboration. The company, with 100 employees, is based in Stockholm, Sweden, with local offices in Denmark, Germany, The Netherlands, and Norway. For more information, please visit www.projectplace.com

innkapNews - 18 April, 2009 - InnovationsKapital: Ignis ASA Acquires Syntune AB

2009-04-20 11:37:18

The acquisition will widen the Ignis product range to include active components, and together with the existing passive components portfolio provide a broader optical offering to network operators. Ignis will issue 8.05 million shares as compensation for 100 % of the shares in Syntune AB to the sellers, which include the leading institutional investors InnovationsKapital and Vision Capital, and founders. Syntune will have a cash position of approximately SEK 25 million prior to the acquisition, and interest bearing debt of approximately SEK 41.8 million. In addition Syntune has established a new loan facility of EUR 2.3 million, Syntune's cash position is considered sufficient to fund its activities until break even during 2010. The company completed the qualification of its first generation of products in 2007. Ramp-up of revenue began at the end of 2007, and amounted to gross SEK 18 million in products sold in 2008, with a significant growth speed into 2009. With Syntune as a 100 % owned subsidiary, Ignis will strengthen its technology platform in a crucial area, tunable laser technology, and in addition get some of the best expertise in the optical industry. Tunability is becoming one of the most critical elements of the optical industry, as wavelength agility offers cost reductions and increased flexibility for optical network operators. Ignis ASA signed a Letter of Intent to acquire Syntune AB earlier in April. After the approval by the Board of Directors in Ignis, the acquisition remains contingent on approval by the General Meeting in Ignis ASA. By acquiring Syntune, Ignis maintains its strategy in taking an active part in the ongoing global industry consolidation. A detailed stock exchange notification about the transaction will follow on Monday the 20th of April. On the same day the company management will present further details about the acquisition at 10 am, at the Felix Conference Centre, Aker Brygge. The presentation will be published via webcast. See Ignis homepage. About Ignis ASA Ignis ASA comprises the business division Ignis Technology, which includes 69.3% ownership in Fi-ra Photonics in Korea and the wholly owned subsidiary Ignis Photonyx - with operations in Denmark, Norway and Canada. Fi-ra is first and foremost provider of optical splitters to large system houses and telecom operators in South-East Asia,while Ignis Photonyx over the last years has been focusing on investing in the development of AWG`s for the next generation high-capacity broadband network WDM-PON. About Syntune AB Syntune AB (www.syntune.com) supplies state-of-the-art widely tunable lasers for applications ranging from fiber-optic communications to sensor systems. In communications, Syntune's lasers enable universal DWDM transceivers with low power consumption in a small form factor. These drastically reduced overhead costs for sparing and maintaining inventories. Tunability also enables flexible networks, which allows operators to offer innovative services and reduces their operational expenditures. About InnovationsKapital InnovationsKapital is a leading independent venture capital firm in the Nordic region with capital commitments of EUR 317 million in four funds. Years of experience and a strong network within academia and industry enable us to invest in successful early stage and growth companies. We support talented entrepreneurs to help them create successful high growth businesses. Since 1994, we have made over 58 investments and a number of successful exits in the life sciences and technology sectors. For further information, please contact: Thomas Ramm, CEO, Ignis ASA Tel: +47 913 70 795

innkapNews - June 18, 2008 - InnovationsKapital: CapMan and InnovationsKapital invest in Crayon

2008-07-27 00:00:00

Crayon advises its clients in software procurement processes and simplifies the clients' software license administration. In addition Crayon offers consulting and training around the purchased software to its clients, which include a number of large Nordic customers within both private and public sectors. The company was founded in 2002 and it has headquarters in Oslo and offices in Trondheim, Stockholm, Umeå, Copenhagen and Helsinki. Crayon's net sales totalled some MEUR 48 in 2007 and the company employs some 190 people. “The company has a truly unique offering in software asset management, combining the work normally done by a value added reseller with skilled management consulting, which has resulted in a strong growth in sales and very satisfied customers”, says CapMan's Investment Director Julia Reuszner. “Crayon has a very strong market position both in Norway and Sweden and we believe there is potential to develop this further and address new geographies and a wider customer base”, says InnovationsKapital's Investment Director Martin Falkevall. “For us the investment made by CapMan and InnovationsKapital is a great acknowledgement of what Crayon has achieved over the last years .We believe that the investment can help us to the next level in our growth ambition”, says Crayon's Chairman of the Board Jens Rugseth. CapMan Technology 2007 fund and InnovationsKapital will own 20% of Crayon's parent company Artix's shares with equal holdings after the transaction has been completed. The current owners, including management and employees, will hold the reminder of the shares. The closing of the transaction is subject to certain conditions agreed with the parties in the transaction to be met. CapMan Plc is a substantial investor in CapMan Technology 2007 fund. For more information, please contact: Julia Reuszner, Investment Director, CapMan Technology tel. +46 8 545 854 70 or +46 739 865 664 Martin Falkevall, Investment Director, InnovationsKapital tel. +46 8 54 50 14 90 or +46 708 47 73 16 Jens Rugseth, Chairman of the Board, Crayon tel. +47 22 89 10 00 or +47 91 16 94 40 CapMan www.capman.com CapMan is one of the leading alternative asset managers in the Nordic countries and manages Nordic funds with approximately EUR 3.1 billion in total capital. CapMan has five investment areas (CapMan Buyout, CapMan Technology, CapMan Life Science, CapMan Russia and CapMan Real Estate), and each of them has a dedicated team and funds. Altogether CapMan employs 130 people in Helsinki, Stockholm, Copenhagen, Oslo and Moscow. CapMan was established in 1989 and its B shares are listed on the Helsinki Stock Exchange since 2001. InnovationsKapital www.innkap.se InnovationsKapital is a leading independent venture capital firm in the Nordic region with capital commitments of EUR 317 million in four funds. Years of experience and a strong network within academia and industry enable us to invest in successful early stage and growth companies. We support talented entrepreneurs to help them create successful high growth businesses. Since 1994, we have made over 58 investments and a number of successful exits in the life sciences and technology sectors. Crayon www.crayon.no Crayon is a successful provider of software asset management and licenses, consulting services and training courses. Established in 2002, Crayon has operations in Norway, Sweden, Finland and Denmark and employs 190 people.

innkapNews - July 8, 2008 - Xtract: Xtract, Innovator in Social Advertising Intelligence Raises EUR 7.5 Million

2008-07-08 00:00:00

London, UK and Helsinki, Finland – July 8, 2008: Xtract, the leader and innovator in social advertising intelligence today announced that it has closed its series B round of funding with EUR 7,5 Million ($11.74M) from leading early-stage technology investors Creandum, ETF III advised by Eqvitec Partners and InnovationsKapital. Xtract enables mobile and online companies to refine their customer data creating highly accurate 3 Dimensional profiles combining social interactions, behaviour and demographic information. It answers a crucial need in the advertising industry by making the advertising in social media and mobile effective. By using Xtract, customers have seen the average ad income increase with as much as 82% and in mobile campaigns response rates have increased, on an average, with 30%. Staffan Ingeborn, Managing Investment Director of InnovationsKapital comments: “Xtract is a very exciting company with a unique proposition for targeting of digital advertising. Its solutions have been shown to create substantial value for its customers, and we believe that Xtract is very well positioned to become a winner and a leader in this space.” Xtract works with over 50 companies with intensive customer data ranging from global leaders such as Nokia, T-Mobile and Vodafone to innovative challengers such as BLYK and Flirtomatic. Xtract makes complexity simple and actionable via a unique and patented set of products that based upon social interactions, behaviour data and other dataflow can create accurate and dynamic real-time customer profiles. Xtract can ensure delivery of the right audience to the right commercial message at the right time and accurately report on the effectiveness of any campaign. Something which up until now was not possible. Xtract board member Juha Mikkola of Eqvitec Partners said: “This investment opportunity had a lot of demand and clearly marks the very interesting market and expansion opportunity that Xtract represents in the fast growing social intelligence market.” “We are delighted to have added two new prominent investors, InnovationsKapital and Creandum in addition to our original investor ETF III advised by Eqvitec Partners. This investment round combined with an exceptional organic growth enables us to expand to new markets outside Europe,” says Kimmo Kiviluoto, CEO of Xtract. About Creandum Creandum is a Nordic venture capital firm investing in early-stage technology companies. The firm has 120 million Euros under management and is today the fastest growing independent partnership of its kind in the Nordic region. Creandum invests in innovative companies in high growth markets led by outstanding entrepreneurs. All investment professionals at Creandum have started companies or been part of successful startups. For more information, please visit www.creandum.com About Eqvitec Partners Oy Eqvitec Partners Oy is one of the largest technology focused venture capital and private equity firms in Northern Europe. The company was founded in 1997 and employs 15 investments professionals in Helsinki and Stockholm. Eqvitec Partners currently advises 6 funds with the total capital base of 500 million Euros. The funds invest in technology companies in all phases from start-up to buyouts. At the moment the funds have investments in 40 companies and have carried out 35 exits. More information can be found at www.eqvitec.com About InnovationsKapital InnovationsKapital is a leading independent venture capital firm in the Nordic region with capital commitments of EUR 317 million in four funds. Years of experience and a strong network within academia and industry enable InnovationsKapital to invest in successful early stage and growth companies. InnovationsKapital supports talented entrepreneurs to help them create successful high growth businesses. Since 1994, InnovationsKapital has made over 60 investments and a number of successful exits in the life sciences and technology sectors. For more information, please visit www.innkap.se About Xtract Xtract is the global trusted partner and innovator in Social Advertising Intelligence. We have the technology and competence to turn large user data into cash flow. Our solutions create accurate and automated consumer profiles for mobile and online advertisers based on social interactions, behavioural and demographic data. Xtract operates across Europe and Asia, working with over 50 companies with intensive customer data ranging from global leaders such as Nokia, T-Mobile and Vodafone to innovative challengers such as BLYK and Fonecta. Headquarters are in Helsinki, Finland and London, UK. www.xtract.com

innkapNews - June 27, 2008 - InnovationsKapital: Isconova secures 30 million Swedish kronor growth financing

2008-06-27 00:00:00

Leading vaccine adjuvant provider set to grow in animal vaccine market and to unlock the value of its technology for human vaccines. Uppsala, 27 June 2008. Isconova AB, announced today that it has secured financing of 30 million Swedish kronor ( 3,3 m€ ) from InnovationsKapital, a leading Nordic venture capital firm, and a group of private investors. Isconova is a pioneer in vaccine adjuvant technology, with a proprietary, safe and effective ISCOM technology. ”We are extremely pleased to have attracted the support of InnovationsKapital, who have a successful record of backing innovative growth biotech companies in Scandinavia. This new investment will allow Isconova to increase our production capacity and to invest in marketing,” said Bengt Falk, Isconova's CEO. “It will enable us to build on our existing growth in the animal vaccine sector. We will also be able to accelerate our activities in human vaccines where we already have a very promising partnership on an influenza vaccine.” Isconova's scientific excellence in the vaccine adjuvant field is backed by commercial validation through several agreements with major healthcare partners and on-market veterinary vaccines. “We feel excited about Isconova's future,” commented Johan Rask and Ulf Tossman at InnovationsKapital. Isconova's adjuvant makes vaccines more protective and longer-lasting. This fills a critical need for safe and effective adjuvants in the fast-growing vaccine industry. Isconova has established a significant production capacity in Uppsala and is already supplying its Matrix adjuvant to corporate partners for use in animal vaccines. For further information please contact: At Isconova: Bengt Falk, CEO, Isconova phone +46 703 022254 email bengt.falk@isconova.se At InnovationsKapital: Ulf Tossman, Investment Director, InnovationsKapital phone +46 705 630858 email ulf.tossman@innkap.se Johan Rask, Investment Manager, InnovationsKapital phone +46 708 946060 email johan.rask@innkap.se About Isconova AB, www.isconova.se Isconova, based in Uppsala, Sweden was established in 2000 by scientists from the Swedish Agricultural University. The Company's mission is to use its safe and effective ISCOM technology platform to deliver innovative vaccines. ISCOM is already established as the dominant vaccine adjuvant for horse vaccines in Europe. Isconova has licensed its technology to major vaccine corporations, including Intervet, Schering Plough, Pfizer and Crucell. Isconova will continue to drive growth by extending the use of its adjuvant into dogs, cats and livestock. New developments will allow Isconova to develop research projects to explore the use of ISCOM in human vaccines. About InnovationsKapital, www.innkap.se InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. To date, more than 60 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 317 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors.

innkapNews - June 11, 2008 - Syntensia: Syntensia Secures Expansion Financing - Leading Network Security-on-Demand Company Charts Further Growth in Emerging Markets

2008-06-11 00:00:00

NEW YORK, June 3, 2008 - Syntensia AB, a pioneer in subscription Network Security-On-Demand solutions, has secured financing of $3.5 million with an option for an additional $4 million through a share issue directed to InnovationsKapital, a leading Nordic venture capital firm, and a group of private investors in Sweden and abroad. Syntensia chairman is John Wattin. Syntensia, headquartered in Stockholm and with sales offices in twenty major Indian cities, Philippines and Cambodia was established in 2005 by Kaushik Thakkar. It focuses on providing all-in-one network security solutions for SMB in high growth emerging markets. "This investment allows Syntensia to continue our solid growth in India and our expansion in Cambodia and the Philippines," said Syntensia CEO Johan Hansson. "It also makes possible expansion into other Asian markets. We are particularly pleased to have attracted the support of InnovationsKapital, which has a reputation for backing innovative growth companies in Scandinavia." “Syntensia is capitalizing on the powerful combination of a low cost, high demand product offering to fast growing markets. We are very pleased with our investment in Syntensia and feel very excited about the company's potential,” said InnovationsKapital's Investment Director Magnus Berglind. Syntensia's WK product series is the most cost-effective and comprehensive network security solution for SMB available in the market today. These hardware-based appliances are Plug and Play ready, all-in-one network security solutions that integrate seven crucial security check points - Firewall, VPN, Intrusion Protection, Anti Virus, Spam Elimination, Surf Protection and Spyware Guarding and are available for a nominal subscription fee. Syntensia’s subscription model typically bundles everything into its single subscription fee, including automatic updates, maintenance and 24X7 technical support, thus enabling organizations to eliminate upfront costs, providing a predictable cost structure, and ensuring quality of service and the freedom to re-evaluate the solution decision any time. For further information please contact: Johan Hansson, CEO, Syntensia Phone: +1 917 582 0753 Email: johan@syntensia.com Magnus Berglind, Investment Director, InnovationsKapital Phone: +1 917 582 0396 Email: magnus.berglind@innkap.com InnovationsKapital InnovationsKapital (www.innkap.com) was founded in 1994 and is a leading independent venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in and Stockholm, Gothenburg and New York, is focused on investments within ICT and Healthcare & Life Sciences – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. The capital is provided by highly reputable Swedish and international institutional investors. Syntensia AB Syntensia AB (www.syntensia.com) is a European Company headquartered in Stockholm, Sweden. Established in 2005, Syntensia is a pioneer in Security on-demand solutions sold on subscription basis. Syntensia focuses on providing all-in-one network security solutions for SMB in high growth emerging markets.

innkapNews - Sept 24, 2007 - InnovationsKapital: Apptus expands with help of InnovationsKapital

2007-09-24 00:00:00

Apptus Technologies AB - a Swedish challenger in the global market for search technology in the e-directory and e-commerce sector - announced today that InnovationsKapital, the leading Nordic private equity/venture capital fund has become a new investor in the company. Since its founding in 2000, Apptus Technologies has positioned itself as the leader in the e-directory and e-commerce sector in the Nordic countries. As a result, Apptus' technology platform is currently used by top tier customers such as, Eniro, Hitta and CDON.COM. In collaboration with InnovationsKapital, Apptus will increase its efforts on international expansion, continue the strong focus on sales and broaden the Apptus product portfolio. "With InnovationsKapital in our corner, we can scale up operations and take aggressive measures to become a leading international player in search technology. We have recently won our first customers in England and Canada, and we see this as a springboard out into the world," says Apptus CEO Michael Atlevi. "Apptus is a very exciting company with a unique offering to its customers, as well as strong and proven products and an impressive Nordic customer base. We are looking forward work with the Apptus team to build on their already widely successful Nordic presence. We strongly believe Apptus has the potential to become a dominating player in the global marketplace," says Martin Falkevall, Investment Director at InnovationsKapital. "Apptus position in the Nordic market has improved dramatically during 2007. We continue building our world class team, expand our product line and increase sales by 70 percent this year. InnovationsKapital will take an active role on our board of directors, bringing a strong track record and extensive experience in international expansion. We are launching several major initiatives for which we are well-equipped, thanks to our stable foundation, both when it comes finances and expertise," says Gertrud Elisabet Bohlin, Chairperson of the Board, Apptus Technologies AB. For more information, please contact: Gertrud Elisabet Bohlin, Chairwoman of the Board, Apptus Technologies AB Phone: +46 705-669526 E-mail: geb@queenab.se Martin Falkevall, Investment Director, InnovationsKapital Phone: +46 708- 47 73 16 E-mail: martin.falkevall@innkap.se More about Apptus Apptus Technologies AB is leading in search and database technology in the Nordic countries. The company provides solutions and products that assure availability for customers with growing data volumes and stringent demands on search logic, relevant results and connections to customers' operations. Apptus primarily supplies solutions to customers in the e-directory and e-commerce sector. Among the Nordic customers are Bokus, CDON.COM, De Gule Sider, Eniro, Hitta.se, Lunarstorm, Sveriges Radio, Torget Sverige, etc. Apptus conducts research in search and database technology. Apptus stands for quality, results and growth. For more information, please visit http://www.apptus.com. More about InnovationsKapital InnovationsKapital was founded in 1994 and is a leading early stage venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT, Healthcare & Life Sciences and Clean Tech - dynamic sectors that are rapidly expanding and where Nordic research plays an important role. InnovationsKapital currently advises four venture funds aggregating EUR 320 million in committed capital. The capital is provided by international institutional investors. For further information, please visit http://www.innkap.se

innkapNews - June 13, 2007 - InnovationsKapital: InnKap finansierar gräddan

2007-06-13 00:00:00

Innovationskapital handplockas endast de bästa projekten den skandinaviska marknaden och inför framtiden hoppas Gunnar Fernström, som är partner Innovationskapital och ansvarig för Health Careinvesteringar, att kunna finansiera bolag som kan erbjuda ny medicinsk teknik för att kunna avlasta sjukvården. "Generellt sett finansieras i dag färre bolag men kvaliteten bland dem som når marknaden har blivit betydligt högre," säger Fernström. Sedan Gunnar Fernström startade på Innovationskapital 1998 har branschen förändrats i positiv riktning. "Det har hänt enormt mycket under de senaste tio åren. Förutom att vi i dag är mycket noggrannare med vilka objekt vi väljer att finansiera, så har också medvetenheten och intresset bland forskarna för att kommersialisera resultat av sin forskning ökat markant," konstaterar Gunnar Fernström. "1998 var det ganska få som visade intresse för att gå ut i bolag med sitt forskningsresultat. I dag tror jag att de allra flesta som arbetar med forskning i olika program känner till att det finns möjlighet att starta verksamhet och att deras forskning kan komma ut i bolag." Innovationskapital investerar i de mest intressanta bolagen, främst i Skandinavien, med ett perspektiv på 5-7 år men ibland längre. Bolaget erbjuder stor expertis och nätverkskontakter under hela investeringsoch utvecklingsprocessen. Endast de bästa bolagen handplockas. "Förutsättningen för en finansiering är att produkten möter ett riktigt bra medicinskt behov som inte någon annan tillgodoser. Det kan vara både inom medicinsk teknik, läkemedel eller diagnostik," säger Gunnar Fernström. Framtidens bolag "Framtiden tror jag handlar om att hitta terapier inom medicinsk teknik som kan avlasta sjukvården genom att förkorta vårdtider och förbilliga vård. Forskningsresultat som leder till att människor kan behålla god livskvalitet, trots hög ålder, är viktiga saker," framhåller Fernström och funderar över förutsättningarna för morgondagens bolag. Fernström menar att det skulle vara av nytta för företagarvärlden om det inom universitetens ram skapades mer utrymme för entreprenörsbiten. Det skulle i sin tur leda till att mognare bolag plockades upp av venture bolagen. "Mot slutet av 2000-talet var det många bolag som kom till marknaden utan att de var riktigt mogna. Med mer 'mjuka pengar' in i universitetssystemet för att klara av de initiala finansieringarna som att söka de första patenten, skriva en affärsplan samt göra en marknadsundersökning, kommer förutsättningarna för lyckosamma affärer att öka ännu mer.

innkapNews - May 4, 2007 - InnovationsKapital: Hexaformer expands following investment from InnovationsKapital

2007-05-04 00:00:00

Hexaformer, a Swedish challenger on the global market for distribution transformers, today announced that the leading Nordic private equity/venture capital investment firm, InnovationsKapital, invests 30MSEK in the company. The investment makes it possible to expand sales and production for Hexaformer’s patented distribution transformers. During several years, Hexaformer has worked intensively to develop a new generation transformer, one that is significantly better and cheaper to produce compared to a conventional transformer. Up until now, Hexaformer has primarily sold prototypes, and smaller series of the new transformer – a total of 700 units have been sold to, among others, Vattenfall, Eon, Fortum, and Jämtkraft. “The investment from InnovationsKapital makes it possible to ramp up production and sales, and make an aggressive bet on becoming a leading vendor of distribution transformers to customer all over Europe. A fully automated production line, with an initial capacity of 1,500 transformers per year, is being built in Västervik”, says Magnus Palmstierna, CEO of Hexaformer. ”Hexaformer is a very exciting company with a unique value proposition, a strong patent portfolio, and a great market position in the Nordic countries”, says Martin Falkevall, Investment Director at InnovationsKapital. In connection to the investment from InnovationsKapital, the board of directors will be expanded and strengthened. Sören Swärd will be among those added to the board. Sören has extensive experience from the sector, and formerly served as the CEO of Siemens Sweden AB. “In my previous role as CEO of Siemens Sweden, I followed Hexaformer’s development during an extended period of time. The fact that Hexaformer’s transformers were significantly better than the conventional kind was something that I understood very early. I am now even more convinced about the products superiority, and I am excited to take part in the company’s plans for the future. I hope that my long industrial experience and the network that I have built up over the years will contribute positively to the company’s development going forward”, says Sören Swärd. For more information, please contact: Magnus Palmstierna, CEO, Hexaformer, telephone +46 70 590 15 65, e-mail: magnus.palmstierna@hexaformer.com Mattias Klintemar, CFO, Hexaformer, telephone +46 709 32 64 67, e-mail: mattias.klintemar@hexaformer.com Martin Falkevall, Investment Director, InnovationsKapital, telephone +46 708 47 73 16, e-mail: martin.falkevall@innkap.se About Hexaformer: Hexaformer is a Swedish company developing, manufacturing, and selling the market’s most efficient transformers and reactors. The transformers are covered by a global patent, based on an innovation by Lennart Höglund. Patent applications have also been filed for the company’s reactor solutions. The company is ramping up a large scale, highly automated production in Västervik. The company delivered its first hexatransformer for commercial use in year 2000, and has since delivered about 700 hexatransformers to a variety of customers, including smaller electricity boards, to large demanding customers such as Vattenfall, Eon, Fortum, Scania and Atlas Copco. The company has, up until InnovationsKapital’s investment, been financed by its CEO, Magnus Palmstierna, Bliwa Livförsäkring, Saminvest, and some 20 private investors. For more information, please visit our home page: http://www.hexaformer.com About InnovationsKapital: InnovationsKapital was founded in 1994 and is a leading venture capital firm for innovative growth companies. The business is focused on Nordic investments within Information & Communication Technology (ICT), Healthcare & Life Sciences and Clean Tech – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. InnovationsKapital has invested in over 55 companies, and examples of successful exits are Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Formex, Kreatel, Nordnav and Spotfire. InnovationsKapital currently advises four venture funds aggregating EUR 320 million in committed capital. The capital is provided by international institutional investors. For further information about InnovationsKapital, please visit our home page: http://www.innkap.se

innkapNews - May 3, 2007 - InnovationsKapital: Spotfire acquired for 195 MUSD - InnovationsKapital makes a return on investment of 9X in cash

2007-05-03 00:00:00

The IT company Spotfire has been acquired by TIBCO, a US software company quoted on Nasdaq. As a result of the deal, InnovationsKapital’s first fund, InnKap 1, can now be closed. The performance of this fund has been outstanding with investors receiving a return in excess of 7x on their investment. As a result InnKap 1 has achieved a unique position amongst the very best early stage European venture capital funds of this vintage. Spotfire achieved a return, in cash, of 9X of the investment and for InnovationsKapital, Spotfire is another success story in a line of recent successful investments. During the past year, thriving businesses such as Kreatel, Carmen Systems and Nordnav, have been sold with exceptional returns. “Since we started in 1994, we have completed almost 60 investments and achieved 30 exits. The exit in Carmen Systems last year was awarded “The Exit of The Year”, by both the Swedish Private Equity & Venture Capital Association and Nordic Unqoute. This continues to confirm that our early stage investment strategy is a successful model when the longer term perspective is taken””, says Staffan Ingeborn, CEO of InnovationsKapital and responsible for the investment in Spotfire. Outstanding result in InnKap 1 As a result of the exit in Spotfire, InnovationsKapital’s first fund can now be closed with this outstanding result. Four out of the eighteen investments in the fund have each yielded more than a 9X return on investment. “Those institutions who invested in our fund have received 7X the invested capital in net yield. It places us in a unique position in Europe. It’s exceptional to have so many first-rate investments in the same fund”, says Staffan Ingeborn. From research project to world leading company in ten years Spotfire, which was one of InnovationsKapital’s earlier investments, had its origins in a research project at Chalmers University of Technology which was led by Christopher Ahlberg, the CEO and founder. Today, ten years later, Spotfire is a global leader in its niche segment of the software market, with 7 out of 10 of the largest companies in the world on the customer list. Building for long term success “Many entrepreneurs are interested in an investment partnership with InnovationsKapital but we only invest in companies where we believe that there are good growth prospects on the international market. This proved to be the case for Spotfire, which is now joining our other success stories”, says Staffan Ingeborn. “Besides the necessary capital, InnovationsKapital have contributed with a great deal of experience in building growth companies together with an exceptional network of contacts. They helped us to think and act ‘as a business’ in a long term and focused way. Now, Spotfire is progressing well and is ready to take the next leap forward together with the new shareholders. This means that the business will progress and be further strengthened”, says Christopher Ahlberg, CEO and founder of Spotfire. Searching for “new Spotfires” ”We are on the hunt for new Spotfires. We are currently spending a significant amount of time and effort seeking new early stage high growth companies for InnKap 4, our latest fund. We have already found several very interesting investment opportunities which we believe will have every chance of succeeding, like Spotfire, and we will continue to work on them together with those potential pots of gold which we already have in our portfolio”, says Staffan Ingeborn. Media Enquiries: Staffan Ingeborn, CEO InnovationsKapital +46 (0)70 583 14 34 Advisors to the Investor Consortium and Management: • Financial: Goldman Sachs • Legal: Foley Hoag LLP InnovationsKapital was founded in 1994 and is a leading early stage venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT, Healthcare & Life Sciences and Clean Tech – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. InnovationsKapital currently advises four venture funds aggregating EUR 320 million in committed capital. The capital is provided by international institutional investors. For further information, please visit http://www.innkap.se

innkapNews - Mar 22, 2007 - InnovationsKapital: SVCA Awards 2007 - Årets prisbelönade private equity-bolag

2007-03-22 00:00:00

Industri Kapital, Creandum och InnovationsKapital belönades i går på Svenska Riskkapitalföreningens heldagskonferens med utmärkelserna Årets mest samhällsnyttiga investering, Årets kapitalanskaffning respektive Årets exit. Priset för Årets mest samhällsnyttiga investering eller projekt tilldelades Industri Kapital för projektet för bekämpning av sömnsjukan i Uganda. I samarbete med två portföljbolag, myndigheter i Uganda samt universitet i Skottland och Uganda har Industri Kapital bedrivit ett projekt med syftet att stoppa sömnsjukans spridning, och att förhindra mutation till en ny form av sjukdomen. Projektet har på ett innovativt sätt kombinerat Industri Kapitals finansiella resurser och erfarenhet av projekthantering med materiella resurser och specialistkompetens från två av Industri Kapitals portföljbolag. Projektet visar hur positiva resultat kan åstadkommas genom samverkan mellan näringsliv, universitet och myndigheter, även när parterna finns i spridda delar av världen. Övriga nominerade var Procuritas projekt Charity Rating och Swedfunds investering i Addis Cardiac Hospital. Creandum tilldelades SVCA Awards för årets kapitalanskaffning. Creandums team genom förde kapitalanskaffningen till sin andra fond, Creandum II under en för venture-fonder mycket kort tid, 100 dagar. Fonden, om 750 miljoner kronor, är inriktad på teknikbolag i tidiga skeden. Investerarkretsen utökades från de två ursprungliga svenska investerarna till ett flertal välrenommérade institutioner, merparten internationella. Övriga nominerade var fonderna Northzone V och EQT V. InnovationsKapital tilldelades priset för Årets exit för försäljningen av Carmen Systems till Boeing Company. Under InnovationsKapitals sju år som ägare utvecklades Carmen Systems från ett litet venture till ett företag med 300 anställda. Genom att tillföra ett långsiktigt ägarperspektiv, industriell kunskap och ett aktivt ägar engagemang bidrog InnovationsKapital till att utveckla Carmen till en ledande aktör inom sitt segment. Vid försäljningen gjorde InnovationsKapital en vinst på 9 gånger insatt kapital. Övriga nominerade var 3i, InnovationsKapital, SMAC för försäljningen av Nordnav Technologies och Bridgepoint Capital för försäljningen av CarPark. Fotografier av pristagarna finns att ladda ner från http://www.svca.se För mer information, var god kontakta: VD Tom Berggren, (SVCA), 070- 8600 500 eller e-post: tom.berggren@svca.se

innkapNews - Mar 21, 2007 - InnovationsKapital: SVCA Awards 2007 - Årets prisbelönade private equity-bolag

2007-03-21 00:00:00

Industri Kapital, Creandum och InnovationsKapital belönades i går på Svenska Riskkapitalföreningens heldagskonferens med utmärkelserna "Årets mest samhällsnyttiga investering", "Årets kapitalanskaffning" respektive "Årets exit". Priset för Årets mest samhällsnyttiga investering eller projekt tilldelades Industri Kapital för projektet för bekämpning av sömnsjukan i Uganda. I samarbete med två portföljbolag, myndigheter i Uganda samt universitet i Skottland och Uganda har Industri Kapital bedrivit ett projekt med syftet att stoppa sömnsjukans spridning, och att förhindra mutation till en ny form av sjukdomen. Projektet har på ett innovativt sätt kombinerat Industri Kapitals finansiella resurser och erfarenhet av projekthantering med materiella resurser och specialistkompetens från två av Industri Kapitals portföljbolag. Projektet visar hur positiva resultat kan åstadkommas genom samverkan mellan näringsliv, universitet och myndigheter, även när parterna finns i spridda delar av världen. Övriga nominerade var Procuritas projekt Charity Rating och Swedfunds investering i Addis Cardiac Hospital. Creandum tilldelades SVCA Awards för årets kapitalanskaffning. Creandums team genom¬förde kapitalanskaffningen till sin andra fond, Creandum II under en för venture-fonder mycket kort tid, 100 dagar. Fonden, om 750 miljoner kronor, är inriktad på teknikbolag i tidiga skeden. Investerarkretsen utökades från de två ursprungliga svenska investerarna till ett flertal välrenommérade institutioner, merparten internationella. Övriga nominerade var fonderna Northzone V och EQT V. InnovationsKapital tilldelades priset för Årets exit för försäljningen av Carmen Systems till Boeing Company. Under InnovationsKapitals sju år som ägare utvecklades Carmen Systems från ett litet venture till ett företag med 300 anställda. Genom att tillföra ett långsiktigt ägarperspektiv, industriell kunskap och ett aktivt ägar¬¬engagemang bidrog InnovationsKapital till att utveckla Carmen till en ledande aktör inom sitt segment. Vid försäljningen gjorde InnovationsKapital en vinst på 9 gånger insatt kapital. Övriga nominerade var 3i, InnovationsKapital, SMAC för försäljningen av Nordnav Technologies och Bridgepoint Capital för försäljningen av CarPark.

innkapNews - Jan 15, 2007 - InnovationsKapital: Swedish GPS start-up Nordnav sold for $75m

2007-01-15 00:00:00

- World leader in Bluetooth technology, CSR, strengthens its product portfolio through acquisition 3i Group plc, InnovationsKapital and smac partners together with Nordnav’s management, have agreed to sell Nordnav, a Swedish pioneer in next generation GNSS receivers, to Cambridge Silicon Radio (LSE: CSR.L). The purchase price for all shares in the company is approximately $75 million. InnovationsKapital and 3i co-led the first investment round in Nordnav in May 2005. Kimmo Korpela, Director, 3i Nordic, comments on the sale:”This transaction has very clear logic in the industry and is a very good outcome for Nordnav and its shareholders. We, at 3i, are especially delighted to have demonstrated our value by introducing Nordnav to CSR, a highly successful company and originally a 3i investment.” Peder Holm, Investment Director, InnovationsKapital, says: “This is a successful investment that will generate up to 8 times our total investment in the company.” Nordnav, which was founded 2002 by two researches from Luleå University and Stanford University, Per Ludvig Normark and Dennis Akos, is today a market leader in the software GNSS receiver market, providing the only genuinely working GPS software solution for mobile devices. Nordnav develops and licenses software receivers for GPS and Galileo that offer both better performance and significant cost savings compared with alternatives. The company’s solutions enable high quality location functionality to be built into any portable device, including mobile phones, PDAs, and automotive navigation systems. Fredrik Cronqvist, Investment Manager, InnovationsKapital, adds: “We believe that CSR is a great industrial partner that can make a large and successful business out of Nordnav’s world leading GPS technology. This acquisition will enable CSR to provide GPS in mass-market mobile handsets at a significantly lower price compared to competitors.” CSR plc is a world leader in Bluetooth technology, which 3i co-founded as part of a syndicate in 1999 and helped to float on the London Stock Exchange in 2004. Arma Partners has acted as the vendor’s advisor in the transaction. For further information, please contact: Kimmo Korpela, Director, 3i Nordic plc, advisor for 3i Group plc: Tel. +46 8 506 101 44, +46 70 348 88 19 Peder Holm, Investment Director, InnovationsKapital: +46 8 54 50 14 93, +46 703 46 57 70 Fredrik Cronqvist, Investment Manager, InnovationsKapital: +46 8 54 50 14 92, +46 703 13 73 33 Dr. Dietrich Ulmer, Managing Partner, smac partners GmbH: +49 89 55 06 88 11, +49 173 53 45 851 Mattias Åström, Chief Executive Officer, Nordnav Technologies: +46 8 39 0000 About 3i 3i is a world leader in private equity and venture capital. We focus on Buyouts, Growth Capital, Venture Capital and Infrastructure and invest across Europe, the United States and Asia. Our competitive advantage comes from our international network and the strength and breadth of our relationships in business. These underpin the value that we deliver to our portfolio and to our shareholders. http://www.3i.com About InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent venture capital firm for innovative growth companies. The investment strategy is focused on Nordic investments within ICT and Healthcare & Life Sciences – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. To date, more than 55 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Formex and Kreatel Communications. InnovationsKapital advises four venture capital funds aggregating EUR 317 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at http://www.innkap.se About smac partners smac partners - formerly known as Siemens Acceleration in Communications - is a private equity company specialised in managing venture portfolios worldwide. We are focused on VC deals in ICT worldwide with an exceptional track record. smac partners offers secondary asset transactions and actively manages the respective portfolio companies. In this role we currently advice TempoPark Fund I. Further information about smac partners can be found at http://www.smacpartners.com About Nordnav Nordnav develops and licenses software receivers for GPS and Galileo that offer both better performance and significant cost savings. Our solution enables high quality location functionality to be built into any device, including mobile phones, PDAs, and digital cameras, as well as into automotive navigation systems. Our products are licensed to leading manufacturers in the mobile, automotive, and consumer electronics industries across the world. Nordnav is headquartered in Stockholm, Sweden. Information about Nordnav can be found at http://www.Nordnav.com

innkapNews - Dec 7, 2006 -InnovationsKapital: Carmen Systems - Venture exit of the year

2006-12-07 00:00:00

InnovationsKapital, together with Gilde Investment Fund and GE Capital, won the Nordic Unquote’s award Venture exit of the year - “an outstanding exit of a Nordic company in the past twelve months. It recognises innovation and clear leadership in the venture market.”

In March 2006, Carmen Systems was sold to The Boeing Company, giving net proceeds to InnovationsKapital of SEK 190 million. InnovationsKapital has in total invested SEK 21 million and makes a return on investment of 9X in cash. Since InnovationsKapital’s investment, Carmen Systems has developed into a leading resource optimization solution provider in the railroad and airline industries. “Carmen is a good example on how InnovationsKapital invests in early stage, technology companies in the Nordic region and supports them to grow globally and enter into the world market. The company has had an impressive development during the years of InnovationsKapitals’ participation. We have seen the company grow from a very small venture to 300 employees. The management has succeeded in turning Carmen into a leading international business in its field,” says Gunnar Fernström, Investment Director at InnovationsKapital. Carmen Systems joined the Jeppesen group of companies within Boeing Commercial Aviation Services (CAS). Carmen Systems AB Carmen Systems develops, markets and implements resource optimization software and services solutions for clients in the transportation industry, primarily the airline and railway industries. Clients include, among others; Aeroméxico, Air France-KLM, British Airways, Delta Air Lines, Finnair, Lufthansa, Scandinavian Airlines, Singapore Airlines, Spanair, Virgin Atlantic Airways, Deutsche Bahn (German Railways), Amtrak, Green Cargo, National Rail Enquiries (UK), RailCorp - New South Wales (Australia) and SNCF (French National Railways). Carmen Systems is a rapidly expanding organization and today has 295 employees from 33 nationalities. Carmen Systems’ headquarters is in Göteborg, Sweden with additional offices in Austin (Texas), Brisbane (Australia), Copenhagen, London, Montreal, Singapore and Stockholm. The Boeing Company Boeing is the world's leading aerospace company and the largest manufacturer of commercial jetliners and military aircraft, with capabilities in rotorcraft, electronic and defense systems, missiles, satellites, launch vehicles and advanced information and communication systems. Our reach extends to customers in 145 countries around the world, and we are the number one U.S. exporter in terms of sales. Jeppesen Jeppesen is recognized as the world's foremost provider of information solutions in the aviation and soon-to-be maritime markets. Jeppesen's portfolio includes: worldwide flight information, flight operations services, international trip planning services, aviation weather services and aviation training systems. Jeppesen's marine division will soon produce a full line of navigation solutions and global maritime data services. Jeppesen has offices in the United States, the United Kingdom, Germany, Australia, China, France and Russia. Jeppesen is a subsidiary of Boeing Commercial Aviation Services, a unit of Boeing Commercial Airplanes.

innkapNews - Oct 9, 2006 - InnovationsKapital: Venture Capital Alive and Kicking: SJ Berwin LLP Advises InnovationsKapital on SEK 1 Billion Venture Fund

2006-10-09 00:00:00

Leading private equity firm SJ Berwin LLP advised established client InnovationsKapital on the raising of its fourth venture fund, InnKap 4 Partners with commitments of around SEK 1 billion. The fund will focus on innovative start-up and early stage growth companies operating in the Nordic region and active in the ICT and Healthcare & Life Sciences market sectors. InnovationsKapital is a well established independent early stage venture capital firm. Since 1994, it has completed 56 investments, earned an excellent reputation and is now a preferred venture capital investor for leading entrepreneurs. InnovationsKapital’s aggregated capital under management now amounts to EUR 317 million. Corporate partner, Richard Watkins, who led the SJ Berwin team, commented: “This fundraising is indicative of the beginning of the resurgence of interest in leading venture capital funds in Europe after a few years of being out of favour. InnovationsKapital has a solid track record and shows that investors will continue to back established and successful European venture capital funds” Staffan Ingeborn, CEO at InnovationsKapital added: We are delighted that InnKap 4 Partners has succeeded in attracting so many respected international investors. We owe this success to the solid support from our loyal long-term investors and are pleased to see so many of them taking part in this new fund,” -ends- For further information please contact: Richard Watkins, Corporate Partner on 020 7111 or by emailing richard.watkins@sjberwin.com Aurelia Pretorius, Business Development Manager on 020 7111 2060 or by emailing aurelia.pretorius@sjberwin.com Notes To Editors Founded in 1982, SJ Berwin is a leading City corporate and commercial law firm with more than 550 lawyers working across its offices in London, Berlin, Brussels, Frankfurt, Madrid, Milan, Munich, Paris and Turin. With more than 200 corporate finance lawyers, the depth and breadth of expertise of our pan-European Corporate Finance Department is considerable. We offer the complete range of corporate finance services, which extends to all aspects of domestic and cross-border M&A and buy-outs, private equity, equity capital markets, financial services and tax. SJ Berwin has a leading secondaries practice with extensive experience - both establishing funds to acquire secondary private equity interests, and in doing the deals themselves. We are delighted to have worked with all the leading secondary players in Europe, including Access Capital Partners, Axa Private Equity, Coller Capital, Goldman Sachs, Greenpark Capital, Headway Capital, Natexis Private Equity Opportunities and Vision Capital, advising on the legal, tax and regulatory issues that arise in the structuring and fundraising process as well as transaction structuring and execution. SJ Berwin was created and thrives as a leading-edge legal services business, focusing on the European and international market place. Our clients are sophisticated buyers of legal services, principally entrepreneurial companies and financial institutions, whom we advise on a comprehensive range of services including Corporate Finance, Commercial, Real Estate, Banking, Reconstruction & Insolvency, Financial Services, Litigation, Employment & Pensions, EU & Competition and Tax. Our approach has resulted in the firm winning a number of recent awards including “Fund Formation Team of the Year” 2006 at the Financial News Awards for Excellence in Private Equity Advisory Services, “Law Firm of the Year 2005 at the EVCA/Real Deals European Private Equity Awards for the second successive year,” European Law Firm of the Year (fund formation) by subscribers to PrivateEquityOnline and Private Equity International, Private Equity Law Firm of the Year 2004 at the European Venture Capital journal awards 2004 and 2005, LBO Firm of the Year 2004 at the Finance and Law Awards in Paris, Real Estate Team of the Year at The Lawyer Awards 2004, and World's Leading Firm for Private Funds Expertise in The International Who's Who of Business Lawyers 2003/4. SJ Berwin LLP was named ‘UK Firm of the Year’ at the 2005 Legal Week Awards on 30th November. 2005 The awards recognised SJ Berwin’s five years of international expansion and its involvement in a series of high quality deals. In April 2005 Head of Private Equity, Jonathan Blake, was named Global Lawyer of the Year in the Private Funds category by The International Who’s Who of Business Lawyers 2004/2005. In November 2004, Jonathan Blake, was admitted to the British Venture Capital Association “Hall of Fame” for his services to the private equity industry over the last 20 years.

innkapNews - Oct 6, 2006 - InnovationsKapital: InnovationsKapital secures SEK 1 billion for new investments

2006-10-06 00:00:00

InnovationsKapital, a well established independent early stage venture capital firm, is pleased to announce the closing of the fourth InnKap fund – InnKap 4 Partners. InnovationsKapital’s aggregated capital under management now amounts to EUR 317 million. As with previous funds, InnKap 4 Partners will focus on investing in innovative start-up and early stage growth companies operating in the Nordic region and active in the ICT and Healthcare & Life Sciences market sectors. Since 1994, InnovationsKapital has completed 56 investments, earned an excellent reputation and is now a preferred venture capital investor for top entrepreneurs. We are delighted that InnKap 4 Partners has succeeded in attracting so many respected international investors. We owe this success to the solid support from our loyal long-term investors and are pleased to see so many of them taking part in this new fund,” says Staffan Ingeborn, Managing Investment Director at InnovationsKapital Nordic Advisors AB. Committed capital of EUR 113 million has been raised from a broad mix of Swedish and international investors, including 70 percent of the total from previous investors. Previous investors include Access Capital Partners, Chalmers University of Technology, The First Swedish National Pension Fund, The Third Swedish National Pension Fund, W Capital and The Wellcome Trust. Among the new investors are BP Pension Fund, DnB NOR, Etera, KLP Insurance and Wega Support. In total, the fund has about twenty investors from Europe and the US, with a majority of commitments coming from non-Swedish funds. “The investors have recognised our attractive market position and consistency in terms of track record and proprietary deal access. With our experience from previous funds, coupled with our close co-operation with portfolio companies and our extensive international network, we will help our portfolio companies expand in the global market,” says Peder Holm, Investment Director in the ICT team at InnovationsKapital. The strong deal flow has been confirmed by two new investments in the fund - Ludesi AB and Action Pharma A/S. Ludesi is a global provider of bioinformatics solutions to the life science industry and Action Pharma is dedicated to the discovery and development of novel drugs with significant therapeutic improvement within organ protection in severe cardiovascular diseases. ”The high quality investors in this fund recognize InnovationsKapital’s ability to identify promising healthcare/life science companies and supply them with access to the scientific, capital and management resources critical for success” says Ulf Tossman, Investment Director in the Healthcare/Life Science team of InnovationsKapital. InnovationsKapital has a solid track record. During 2006, Carmen Systems and Kreatel Communications have been sold successfully to Boeing and Motorola respectively. Gothenburg/Stockholm, October 6, 2006 InnovationsKapital Nordic Advisors AB For further information please contact any of the Investment Directors: Staffan Ingeborn +46 31 60 91 91 +46 705 83 14 34 si@innkap.se Gunnar Fernström +46 31 60 91 92 +46 703 12 05 02 gf@innkap.se Peder Holm +46 8 54 50 14 93 +46 703 46 57 70 ph@innkap.se Jonas Risberg +46 8 54 50 14 95 +46 703 78 17 00 jri@innkap.se Ulf Tossman +46 8 54 50 14 91 +46 705 63 08 58 ut@innkap.se Martin Falkevall +46 8 54 50 14 96 +46 708 47 73 16 mf@innkap.se About InnovationsKaptial InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. To date, more than 55 investments have made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Formex and Kreatel Communications. InnovationsKapital advises four venture capital funds aggregating EUR 317 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at http://www.innkap.se

innkapNews - Sep 20, 2006 -InnovationsKapital: Ludesi accelerates growth through InnKap investment

2006-09-20 00:00:00

September 20, 2006, Lund, Sweden. Ludesi AB, a global provider of bioinformatics solutions to the life science industry, today announced that the leading venture capital firm InnovationsKapital invests SEK 25 million in Ludesi. By this transaction InnovationsKapital will join Ludesi´s current investors FöretagsByggarna and the Sixth AP Fund. The funding will allow Ludesi to roll out sales of Ludesi´s innovative and successful offering for image analysis of 2D electrophoresis gels and to expand the company´s product portfolio into other expression proteomics technologies according to customer demands. Ludesi´s image analysis offering is based on world–leading technology for advanced mathematical imaging and an analysis center performing quality–controlled analysis of 2D electrophoresis gels. By using a proprietary software technology in combination with an expert analysis center, Ludesi customers gain benefits in accuracy, throughput and cost. "We are convinced that Ludesi will become a leading player in the protein expression analysis market. Mr Ola Forsstrom–Olsson and his team have proven that they truly have developed a unique product offering and we look forward to working together with them to continue building a successful company", says Gunnar Fernström, Investment Director at InnovationsKapital. Ludesi was established in 2001 by CEO Ola Forsstrom–Olsson, the winner of Medicon Valley Entrepreneurship Award and nominated for MIT Technology Reviews top 100 list of the world´s best technology entrepreneurs under the age of 35. The company has since the founding developed a strong software technology and business model for 2DGE, a key technology in the growing field of expression proteomics. The company will now roll out sales of a successful first offering as well as expand the company´s product portfolio into other expression proteomics technologies. "InnovationsKapital is the leading biotech investor for growth companies in the Nordic region and their engagement in Ludesi is aligned with our building of a world–leading software company in the field of expression proteomics. We are very pleased to have InnovationsKapital as an investor in Ludesi." comments Ola Forsstrom–Olsson, CEO at Ludesi. For further information, please contact: Ola Forsstrom–Olsson, CEO, Ludesi Phone: +46 46 286 5510 Mobile: +46 708 122 548 E–mail: ola.forsstrom–olsson@ludesi.com Gunnar Fernström, Investment Director, InnovationsKapital Phone: +46 31 60 91 92 Mobile: +46 703 120 502 E–mail: gf@innkap.se About InnovationsKapital InnovationsKapital was founded in 1994 and is a leading early stage venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. InnvationsKapital currently advises four venture funds aggregating more than EUR 300 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at http://www.innkap.se About Ludesi AB Ludesi is a global provider of bioinformatics solutions to the life science industry. The company was established in 2001 and is serving some of the most prestigious research facilities in the world with high–quality image analysis of protein gels. Ludesi´s image analysis service is distributed on the internet, allowing companies to get reliable analysis of 2D electrophoresis gels without spending time and money on 2D gel software. The analysis is performed at the Ludesi Analysis Center with world–leading in–house technology to ensure high quality results. By using a specialized analysis center performing 2D gel image analysis, Ludesi customers gain large–scale benefits in accuracy, throughput and cost. This analysis method is rapidly gaining acceptance as the new way of performing image analysis in 2D gel electrophoresis. More information can be found at http://www.ludesi.com

innkapNews - May 30, 2006 - InnovationsKapital: Martin Falkevall joins InnovationsKapital as a new Investment Director in the Information and Communication Technology sector

2006-05-30 00:00:00

Martin Falkevall has joined InnovationsKapital, one of the leading start-up and early stage venture capitalists in the Nordic region, as an Investment Director in the Information and Communication Technology team based in Stockholm. Martin, who is 36, has 9 years experience in the Nordic venture capital industry. He was previously with Capman Capital Management and with Swedestart Management. He joined Swedestart in 1997 as an Analyst, became a Partner in 2000 and remained with them until they were acquired by Capman in 2002, when he became a Partner at Capman. He has a Bachelor of Science degree in Business Administration and Economics and a Master of Science degree in Engineering Physics, both from Lund University. He has been a venture capitalist investing in the Information and Communication Technology sector since 1997 and, as a result, has gained investment experience of the sector for high growth companies requiring seed, start up, early stage and expansion capital in the Nordic region. Martin brings a unique experience of successful early stage investments in the Information and Communication Technology sector and he compliments our team very well, says Staffan Ingeborn, Managing Investment Director of InnovationsKapital. His experience is an excellent fit with our strategic direction and focus and he will play an important role in our current and future investment growth and value creation. I am delighted to join InnovationsKapital, says Martin Falkevall I have great respect for the business approach and competence InnovationsKapital has developed over the years, with a very strong commitment to their portfolio companies and capital growth. The track record of InnovationsKapital is impressive and I am pleased to be part of the company. InnovationsKapital was founded in 1994 and is one of the Nordic regions leading venture capital firms for innovative early stage high growth companies. The business is focused on investments within Information and Communication Technology and HealthCare & Life Science sectors that are rapidly expanding and where Nordic research plays a leading role. The capital is managed in four funds and is provided by highly reputable Swedish and international institutional investors. Stockholm 30 May 2006 For further information please contact: Staffan Ingeborn, Managing Investment Director InnovationsKapital http://www.innkap.se Phone: + 46 31 60 9191 or + 46 70 583 1434 E-mail: staffan.ingeborn@innkap.se Martin Falkevall, Investment Director InnovationsKapital Phone: +46 708 47 73 16 E-mail: martin.falkevall@innkap.se

innkapNews - Sep 20, 2006 - InnovationsKapital: Ludesi accelerates growth through InnKap investment

2006-01-01 00:00:00

September 20, 2006, Lund, Sweden. Ludesi AB, a global provider of bioinformatics solutions to the life science industry, today announced that the leading venture capital firm InnovationsKapital invests SEK 25 million in Ludesi. By this transaction InnovationsKapital will join Ludesi's current investors FöretagsByggarna and the Sixth AP Fund. The funding will allow Ludesi to roll out sales of Ludesi's innovative and successful offering for image analysis of 2D electrophoresis gels and to expand the company's product portfolio into other expression proteomics technologies according to customer demands. Ludesi's image analysis offering is based on world-leading technology for advanced mathematical imaging and an analysis center performing quality-controlled analysis of 2D electrophoresis gels. By using a proprietary software technology in combination with an expert analysis center, Ludesi customers gain benefits in accuracy, throughput and cost. ”We are convinced that Ludesi will become a leading player in the protein expression analysis market. Mr Ola Forsstrom-Olsson and his team have proven that they truly have developed a unique product offering and we look forward to working together with them to continue building a successful company”, says Gunnar Fernström, Investment Director at InnovationsKapital. Ludesi was established in 2001 by CEO Ola Forsstrom-Olsson, the winner of Medicon Valley Entrepreneurship Award and nominated for MIT Technology Reviews top 100 list of the world's best technology entrepreneurs under the age of 35. The company has since the founding developed a strong software technology and business model for 2DGE, a key technology in the growing field of expression proteomics. The company will now roll out sales of a successful first offering as well as expand the company's product portfolio into other expression proteomics technologies. “InnovationsKapital is the leading biotech investor for growth companies in the Nordic region and their engagement in Ludesi is aligned with our building of a world-leading software company in the field of expression proteomics. We are very pleased to have InnovationsKapital as an investor in Ludesi.” comments Ola Forsstrom-Olsson, CEO at Ludesi. For further information, please contact: Ola Forsstrom-Olsson, CEO, Ludesi Phone: +46 46 286 5510 Mobile: +46 708 122 548 E-mail: ola.forsstrom-olsson@ludesi.com Gunnar Fernström, Investment Director, InnovationsKapital Phone: +46 31 60 91 92 Mobile: +46 703 120 502 E-mail: gf@innkap.se About InnovationsKapital InnovationsKapital was founded in 1994 and is a leading early stage venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. InnvationsKapital currently advises four venture funds aggregating more than EUR 300 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se About Ludesi AB Ludesi is a global provider of bioinformatics solutions to the life science industry. The company was established in 2001 and is serving some of the most prestigious research facilities in the world with high-quality image analysis of protein gels. Ludesi's image analysis service is distributed on the internet, allowing companies to get reliable analysis of 2D electrophoresis gels without spending time and money on 2D gel software. The analysis is performed at the Ludesi Analysis Center with world-leading in-house technology to ensure high quality results. By using a specialized analysis center performing 2D gel image analysis, Ludesi customers gain large-scale benefits in accuracy, throughput and cost. This analysis method is rapidly gaining acceptance as the new way of performing image analysis in 2D gel electrophoresis. More information can be found at www.ludesi.com